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NOVEL STATISTICAL APPROACHES FOR MISSING VALUES IN 
TRUNCATED HIGH-DIMENSIONAL METABOLOMICS DATA WITH 
A DETECTION THRESHOLD 
Jasmit S Shah 
April 14, 2017 
 
Despite considerable advances in high throughput technology over the last decade, new 
challenges have emerged related to the analysis, interpretation, and integration of high-
dimensional data. The arrival of omics datasets has contributed to the rapid improvement of 
systems biology, which seeks the understanding of complex biological systems. Metabolomics 
is an emerging omics field, where mass spectrometry technologies generate high dimensional 
datasets. As advances in this area are progressing, the need for better analysis methods to 
provide correct and adequate results are required. While in other omics sectors such as 
genomics or proteomics there has and continues to be critical understanding and concern in 
developing appropriate methods to handle missing values, handling of missing values in 
metabolomics has been an undervalued step.  
Missing data are a common issue in all types of medical research and handling missing data 
has always been a challenge. Since many downstream analyses such as classification methods, 




of missing data is a critical and crucial step. The standard approach used is to remove features 
with one or more missing values or to substitute them with a value such as mean or half 
minimum substitution. One of the major issues from the missing data in metabolomics is due 
to a limit of detection, and thus sophisticated methods are needed to incorporate different 
origins of missingness.  
This dissertation contributes to the knowledge of missing value imputation methods with three 
separate but related research projects. The first project consists of a novel missing value 
imputation method based on a modification of the k nearest neighbor method which accounts 
for truncation at the minimum value/limit of detection. The approach assumes that the data 
follows a truncated normal distribution with the truncation point at the detection limit. The 
aim of the second project arises from the limitation in the first project. While the novel 
approach is useful, estimation of the truncated mean and standard deviation is problematic in 
small sample sizes (N < 10).  In this project, we develop a Bayesian model for imputing missing 
values with small sample sizes. The Bayesian paradigm has generally been utilized in the omics 
field as it exploits the data accessible from related components to acquire data to stabilize 
parameter estimation. The third project is based on the motivation to determine the impact of 
missing value imputation on down-stream analyses and whether ranking of imputation 
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The advent of high-throughput technology to generate massive datasets in biomedical research 
has been on a high rise. Successively, new challenges emerged related to the analysis, 
interpretation, and integration of such data. The diversity of technological advances drives the 
need for efficient analytical methods. Developments in biomedical research within molecular 
biology now allow simultaneous measurements of thousands of cellular components at 
different hierarchical levels, such as genomics, proteomics, transcriptomics, and 
metabolomics. In the “-omics” field, metabolomics is a growing field showing great potential 
in identifying relevant metabolites in biomedical research. It involves the biochemical profiling 
of all the metabolites in a cell, tissue, or organism, and focuses on the best measurement of 
the physiological state of organism’s metabolites (Schmidt, 2004). There has been substantial 
progress in the development of high-throughput methods for metabolomics in the last decade 
with rapid improvements in mass spectrometry (MS)-based methods (Shah et al., 2000), and 
in computer hardware and software that is adept at handling large datasets (Katajamaa and 
Oresic, 2007). A wide range of mass spectrometric techniques have been used in metabolomics 
and the most popular methods used are GC-MS (gas chromatography mass spectrometry), 
LC-MS (liquid chromatography-mass spectrometry) and NMR (nuclear magnetic resonance). 
In spite of the fact that metabolomics has the likelihood of providing understanding to 





Missing values (MV) are challenging since most statistical analyses require a complete dataset. 
They can occur for several different reasons including equipment malfunction, sample 
contamination, and sporadic missed measurements. Many of the studies will have more than 
one type of MV and appropriately handling MVs is important in the inference for a parameter. 
Based on different statistical techniques, MVs are dealt with differently. A common approach 
is to use the complete case analysis method, i.e. removing cases with missing values for any of 
the variables. The other standard approach is done by filling in (imputing) plausible values for 
the MVs, making more efficient use of the data.  Often a study will have more than one type 
of MV, although they are treated as the same kind. Treating each of these types of MVs 
separately has its advantage. One advantage of imputing one type of MV first computationally 
simplifies the imputation of the rest of the MVs. Another advantage is that treating the MVs 
differently allows the researcher to compute how much variability and how much missing 
information is due to each type of MV. Studies which generate high dimensional data can have 
MVs of all three types, categorized as missing completely at random (MCAR), missing at 
random (MAR) and missing not at random (MNAR) (Details in Missing Values section below) 
and to handle MVs with all the types has been an unexplored area of research.  
Metabolomics  
The ‘omics field has become a popular and hot research area in biomedical studies due to its 
detailed content of the cells, tissues, organs or biofluids provided by high throughput 
technologies. Metabolomics is a relatively new area in the omics field, with the term 
“metabolome,” devised less than two decades ago (Oliver et al. 1998). It is the study of small 
molecules (molecular weight < 1,000 Da) in a biological system using high-throughput 
identification and quantification techniques. These molecules, measured simultaneously 




for its selected cellular, tissue or organ levels (Fiehn, 2002). Within the omics cascade, 
metabolomics is further down in line from genomics, proteomics, and transcriptomics and is 
believed to easily correlate with the phenotype as the metabolites serve as direct signatures of 
biochemical activity. Metabolomics comprises the qualitative and quantitative analysis of 
metabolites using two approaches: targeted and untargeted metabolomic analysis. Targeted 
metabolomic analysis focuses on quantitative changes in metabolites of interest (e.g., amino 
acids, carbohydrates, steroids, and fatty acids) based on a priori knowledge of the biological 
function or metabolic pathway whereas untargeted metabolomic analysis involves the 
identification and characterization of a vast number of metabolites and their precursors. 
(Sadanala et al., 2012). The two most relevant technical approaches for the generation of 
metabolomic datasets are mass spectrometry (MS) and nuclear magnetic resonance (NMR). 
MS is an analytical method that obtains spectral data in the form of a mass-to-charge ratio 
(m/z) and a relative intensity of the measured compounds (Alonso 2015).  The biological 
sample first needs to be ionized for the peak signals to be generated for each metabolite. The 
ionized compounds from each molecule will then produce different peak patterns that define 
the impression of the original molecule. Before the MS quantification the separation step is 
performed, where the complexity of the biological sample is reduced to allow the MS analysis 
of different sets of molecules at various times. The most common separation methods used 
are liquid and gas chromatography (LC and GC, respectively) (Theodoridis et al., 2011). The 
LC or GC separation techniques is based on the interaction of the different metabolites in the 
sample with the adsorbent materials used in the chromatography, and thus this way, molecules 
with different chemical properties will require different amounts of time to pass through the 
column. NMR is the other primary approach used based on spectroscopic technique. It relies 




magnetic field (Alonso 2015, Bothwell and Griffin 2011). The quantification of the 
concentrations of molecules are based on the spectral data from NMR, which also provides 
information about its chemical structure.  The spectral peak areas generated by each molecule 
are used as an indirect measure of the quantity of the metabolite in the sample, while the 
pattern of spectral peaks informing on the physical properties of the molecule is used to 
identify the type of metabolite (Alonso 2015).  
 In Figure 1, the conventional pipeline for generating a metabolic profile is shown. The 
typical workflow that is commonly used in high-throughput metabolomic studies starts with 
the processing of the biological samples to produce the metabolic information. Different 
techniques mentioned such as LC-MS, GC-MS or NMR is used for the spectral identification 
and are then processed by various methods. A detailed pre-processing of the spectra data is 
performed using baseline correction, noise reduction, smoothing, peak detection and 
alignment and peak integration. Once the complete set of the metabolic profile has been 
generated, data analysis methods such as univariate and multivariate analyses can be applied 
to study the general structure of the metabolomics data and how different metabolites are 





Figure 1: The analysis workflow in generating a metabolic profile and the various steps of the 






MVs are the unobserved values in a data set which can be of various types and may be missing 
for different reasons. The various reasons why missingness occurs could be due to human 
error, equipment malfunction, dropouts, latent variables. MVs in metabolomics generally arise 
due to a number of reasons, such as: (1) limits in computational detection; (2) imperfection of 
the algorithms whereby they fail in the identification of some of the signals from the 
background; (3) low intensity of the signals used; (4) measurement error; and (5) 
deconvolution that may result in false negative during separation of overlapping signals 
(Gromski et al 2014).  MVs can be problematic across many fields, and appropriate methods 
typically need to be considered when analyzing incomplete data. Knowledge about the nature 
of the missing values can help identify the most appropriate method for dealing with missing 
data (Little & Rubin, 2002). MVs are categorized based on a mechanism where it describes the 
relationship between the probability of a value being missing and the other variables in the 
dataset.  Let 𝑌 represent the complete dataset that can be seperated as (𝑌𝑜𝑏𝑠, 𝑌𝑚𝑖𝑠𝑠) where 
𝑌𝑜𝑏𝑠 is the observed values and 𝑌𝑚𝑖𝑠𝑠 is the missing values. Let 𝑅 be an indicator variable 
indicating whether a value is observed or missing, where 𝑅 = 1 denotes a value which is 
observed and 𝑅 = 0 denotes a value which is missing. The matrix 𝑅 stores the location of the 
MVs and its distribution may depend on 𝑌 = (𝑌𝑜𝑏𝑠, 𝑌𝑚𝑖𝑠𝑠), either by design or by coincidence 
and this relation is described by the missing data model, Pr (𝑅|𝑌 = (𝑌𝑜𝑏𝑠, 𝑌𝑚𝑖𝑠𝑠), 𝜑), where 
𝜑 contains the parameters of the missing data model.  The following are the three mechanisms 




The first mechanism of missingness is missing at random (MAR). If the probability of missing 
is the same within groups defined by the observed data, then the data are MAR. This 
mechanism of missingness is given by  
Pr(𝑅 = 0|𝑌, 𝜑) =  Pr (𝑅 = 0|𝑌𝑜𝑏𝑠 , 𝜑) 
That is the probability of missingness is only dependent on the observed data and not the 
unobserved/missing data. A simple example of MAR is a depression survey where male 
subjects are more likely to refuse to fill out the survey, although it does not depend on the 
level of their depression.  
The second mechanism of missingness is missing completely at random (MCAR). If the 
probability of being missing is the same for all cases, then the data are MCAR. This mechanism 
of missingness is given by  
Pr(𝑅|𝑌, 𝜑) =  Pr (𝑅|  𝜑) 
That is the probability of missingness is not dependent on the observed data and the 
unobserved/missing data. A simple example of MCAR is if a set of household income values 
are missing and if the percentages of missing are equal among ethnicity group, gender, and 
educational group, then the missingness is MCAR, a special case of MAR. 
The third mechanism of missingness is missing not at random (MNAR). If neither MCAR nor 
MAR holds, then it is MNAR, where the probability of being missing is dependent on the 
observed and the unobserved/missing data.  
Pr(𝑅 = 0|𝑌, 𝜑) =  Pr (𝑅 = 0|𝑌𝑜𝑏𝑠, 𝑌𝑚𝑖𝑠𝑠 , 𝜑) 
One example of MNAR is where subjects with severe depression or side effects from the 




Downstream analyses via multivariate methods require a complete dataset. MVs are handled 
differently and thus affects the interpretation and statistical inference. One common approach 
used is case deletion or complete case analysis, wherein this method only completed cases with 
no MVs are included in the analysis. Case deletion leads to a smaller sample size and several 
articles show examples using case removal and results with low power (Harel et al., 2012; 
White & Carlin, 2010). Another approach to handling MVs is via single imputation methods 
where MVs are filled in with plausible values. It is a widely used method and is pretty straight 
forward but also a dangerous way of dealing with missing values. Statistical analysis performed 
on datasets imputed by single imputation method may be biased as the approach does not 
consider the uncertainty of the imputed values. Some of the single imputation methods include 
mean, zero, half minimum and median imputation where the MVs are replaced by the mean, 
zeros, half of the minimum and median of the variable respectively. The magnitude of the 
covariances and correlation also decreases by limiting the variability, and this method often 
causes biased estimates, irrespective of the underlying missing data mechanism (Enders, 2010; 
Eekhout et al., 2012). Other methods in single imputation are based on computation such as 
imputation using k-nearest neighbor (kNN), random forest (RF), Bayesian principal 
component analysis (BPCA), probabilistic principal component analysis (PPCA), and singular 
value decomposition (SVD) imputation. Many of the single imputation methods are 
thoroughly described in Schafer and Graham (2002). Other sophisticated methods of dealing 
with MVs include multiple imputation (Rubin 1987), nonparametric imputation (Wang&Chen 
2009), hot deck imputation (Andridge & Little 2010), weighting techniques (Meng, 1994), 
maximum likelihood (Little and Rubin 2002) via the EM algorithm (Dempster et al 1997) and 
Bayesian analysis (Gelman et al 2003). Most of these methods assume the data is MAR or 




absence in the literature of imputation methods that account for MAR and MNAR 
mechanisms and thus the motivation to develop a method that accounts for both the 
mechanisms.  
Dissertation Outline 
In this dissertation, we develop two novel approaches for imputing MVs which can 
simultaneously handle missing data generated by both MNAR and MAR mechanisms. We 
further investigate the impact of data imputation on statistical analyses. The rest of the 
dissertation is organized as follows. In Chapter 2, we develop a novel missing value imputation 
method based on a modification of the k nearest neighbor method which accounts for 
truncation at the minimum value/limit of detection. The approach assumes that the data 
follows a truncated normal distribution with the truncation point at the detection limit. In 
Chapter 3, we develop a Bayesian model for imputing missing values with small sample sizes. 
The aim of the project arises from the limitation in the previous project. While the novel 
approach is useful, estimation of the truncated mean and standard deviation is problematic in 
small sample sizes (N < 10). The Bayesian paradigm has generally been utilized in the omics 
field as it exploits the data accessible from related components to acquire data to stabilize 
parameter estimation. In Chapter 4, we investigate a comprehensive analysis on the impact of 
missing value imputation on down-stream analyses focusing on differentially expressed 
metabolite detection, classification and clustering analyses. Finally, in Chapter 5 we finish with 








TRUNCATION BASED NEAREST NEIGHBOR IMPUTATION FOR 
HIGH DIMENSIONAL DATA WITH DETECTION LIMIT THRESHOLD 
 
2.1 Background 
High throughput technology makes it possible to generate high dimensional data in many areas 
of biochemical research. Mass spectrometry (MS) is one of the important high-throughput 
analytical techniques used for profiling small molecular compounds, such as metabolites, in 
biological samples. Raw data from a metabolomics experiment usually consist of the retention 
time (if liquid or gas chromatography is used for separation), the observed mass to charge 
ratio, and a measure of ion intensity (Taylor, Leiserowitz et al. 2013). The ion intensity 
represents the measure of each metabolite’s relative abundance whereas the mass-to-charge 
ratios and the retention times assist in identifying unique metabolites. A detailed pre-
processing of the raw data, including baseline correction, noise reduction, smoothing, peak 
detection and alignment and peak integration, is necessary before analysis (Want and Masson 
2011). The end product of this processing step is a data matrix consisting of the unique 
features and its intensity measures in each sample. Commonly, data generated from MS have 
many missing values. Missing values (MVs) in MS can occur from various sources both 
technical and biological. There are three common sources of missingness: (Taylor, Leiserowitz 
et al. 2013) i) a metabolite could be truly missing from a sample due to biological reasons, ii) a 
                                                          





metabolite can be present in a sample but at a concentration below the detection limit of the 
MS, and iii) a metabolite can be present in a sample at a level above the detection limit but fail 
to be detected due to technical issues related to sample processing.  
The limit of detection (LOD) is the smallest sample quantity that yields a signal that can be 
differentiated from the background noise. Shrivastava et al (Shrivastava and Gupta 2011) give 
different guidelines for the detection limit and describe different methods for calculating the 
detection limit. Some common methods (Shrivastava and Gupta 2011)  for the estimation of 
detection limits are visual definition, calculation from signal to noise ratio, calculation from 
standard deviation (SD) of the blanks and calculation from the calibration line at low 
concentrations. Armbruster et al (Armbruster, Tillman et al. 1994) compare the empirical and 
statistical methods based on gas chromatography MS assays for drugs. They explain the 
calculation from SD where a series of blank (negative) samples (a sample containing no analyte 
but with a matrix identical to that of the average sample analyzed) are tested and the mean 
blank value and the SD are calculated, where the LOD is the mean blank value plus 2 or 3 
SDs (Armbruster, Tillman et al. 1994). The signal-to-noise ratio method is commonly applied 
to analytical methods that exhibit baseline noise (Shrivastava and Gupta 2011, Cole, Mills et 
al. 2016). In this method, the peak-to-peak noise around the analyte retention time is measured, 
and subsequently, the concentration of the analyte that would yield a signal equal to a signal-
to-noise ratio (S/N) of three is generally accepted for estimating the LOD (Shrivastava and 
Gupta 2011). 
Missing data can be classified into three categories based on the properties of the causality of 
the missingness (Little and Rubin 2002): “missing completely at random (MCAR)”, “missing 




MCAR if the probability of an observation being missing does not depend on observed or 
unobserved measurements. If the probability of an observation being missing depends only 
on observed measurements then the values are considered as MAR. MNAR is when the 
probability of an observation being missing depends on unobserved measurements. In 
metabolomics studies, we assume that the missing values occurs either as MNAR (metabolites 
occur at low abundances, below the detection limit) or MAR, e.g. metabolites are truly not 
present or are above the detection limit but missing due to technical errors.  The majority of 
imputation algorithms for high-throughput data exploit the MAR mechanism and use 
observed values from other genes / proteins / metabolites to impute the MVs.  However, 
imputation for MNAR values is fraught with difficulty (Karpievitch, Dabney et al. 2012, 
Taylor, Leiserowitz et al. 2013). Using the imputation methods for microarray studies in MS 
omics studies could lead to biased results because most of the imputation techniques produce 
unbiased results only if the missing data are MCAR or MAR (Karpievitch, Stanley et al. 2009). 
Karpievitch et al (Karpievitch, Dabney et al. 2012) discuss several approaches in dealing with 
missing values, considering MNAR as censored in proteomic studies.  
Many statistical analyses require a complete dataset and therefore missing values are commonly 
substituted with a reliable value. Many MV imputation methods have been developed in the 
literature in other -omic studies. For example the significance of appropriate handling of MVs 
has been acknowledged in the analysis of DNA microarray (Troyanskaya, Cantor et al. 2001) 
and gel based proteomics data (Pedreschi, Hertog et al. 2008, Albrecht, Kniemeyer et al. 2010). 
Brock et al (Brock, Shaffer et al. 2008) evaluated a variety of imputation algorithms with 
expression data such as KNN, singular value decomposition, partial least squares, Bayesian 
principal component analysis,  local least squares and least squares adaptive. In MS data 




subjects with missing values from the analysis or to drop the entire subject with a large number 
of missing metabolites. Other standard methods of substitution include using a minimum 
value, mean, or median value. Gromski et al (Gromski, Xu et al. 2014) analyzed different MV 
imputation methods and their influence on multivariate analysis. The choice of imputation 
method can significantly affect the results and interpretation of analyses of metabolomics data 
(Hrydziuszko and Viant 2011).  
Since missingness may be due to a metabolite being below the detection limit of the mass 
spectrometer (MNAR) or other technical issues unrelated to the abundance of the metabolite 
(MAR), we develop a method that accounts for both of these mechanisms. To demonstrate 
missing patterns, Figure 2 summarizes the distribution of two different metabolites taken from 
Sansbury et al (Sansbury, DeMartino et al. 2014), both of which had missing values. The top 
graph shows that the distribution of the metabolite is far above the detection limit and 
therefore replacing the MV in that metabolite with a LOD value would be inappropriate. 
Similarly, the bottom graph shows that the distribution of the metabolite is near the detection 





Figure 2.  Two examples of metabolite distributions which have missing values (MVs), from 
the myocardial infarction data (Sansbury, DeMartino et al. 2014).  
The black vertical line on each graph shows the minimum value of the data, considered as the 
lower limit of detection (LOD).  The small vertical lines below the x-axis in each case indicate 
the observed values of the metabolites.  The figure on the top shows the distribution of 1,2 
dipalmitoylglycerol, where the observed values are all around 3 standard deviations above the 
LOD.  In this case, the MVs are likely to be MAR or MCAR.  In contrast, the figure on the 
bottom shows the distribution of 7-ketodeoxycholate, which is close to the LOD.  Here, the 




In this work, we develop an imputation algorithm based on nearest neighbors that considers 
MNAR and MAR together based on a truncated distribution, with the detection limit 
considered as the truncation point. The proposed truncation-based KNN method is compared 
to standard KNN imputation based on Euclidean and correlation based distance metrics.  We 
show that this method is effective and generally outperforms the other two KNN procedures 
through extensive simulation studies and application to three real data sets (Sansbury, 
DeMartino et al. 2014, DeFilippis, Chernyavskiy et al. 2016).   
2.2 Methods 
K-Nearest Neighbors (NN) 
KNN is a non-parametric machine learning algorithm. NN imputation approaches are 
neighbor based methods where the imputed value is either a value that was measured for the 
neighbor or the average of measured values for multiple neighbors. It is a very simple and 
powerful method. The motivation behind the NN algorithm is that samples with similar 
features have similar output values. The algorithm works on the premise that the imputation 
of the unknown samples can be done by relating the unknown to the known according to 
some distance or similarity function. Essentially, two vectors that are far apart based on the 
distance function are less likely than two closely situated vectors to have a similar output value. 
The most frequently used distance metrics are the Euclidean distance metric or the Pearson 
correlation metric. Let 𝑋𝑖 , 𝑖 = 1,… , 𝑛  be independent and identically distributed (iid) with 
mean µ𝑋 and standard deviation 𝜎𝑋, and 𝑌𝑖  , 𝑖 = 1, … , 𝑛 be iid with mean µ𝑌 and standard 
deviation 𝜎𝑌. The two sets of measurements are assumed to be taken on the same set of 
observations.  Then the Euclidean distance between the two sample vectors 𝒙 =  〈𝑥1, … , 𝑥𝑛〉 








It is the ordinary distance between two points in the Euclidean space. The correlation between 
vectors 𝒙 and 𝒚 is defined as follows: 
𝑟(𝒙, 𝒚) =  
1
𝑛
∑ 𝑥𝑖𝑦𝑖 − µ̂𝑋µ̂𝑌𝑖
?̂?𝑋?̂?𝑌
 
where µ̂𝑋, µ̂𝑌, ?̂?𝑋 ,  and ?̂?𝑌 are the sample estimates of the corresponding population 
parameters. If 𝒙 and 𝒚 are standardized (denoted as 𝒙𝑠 and 𝒚𝑠, respectively) to each have a 








When using the Euclidean distance, normalization/re-scaling process is not required for KNN 
imputation because neighbors with similar magnitude to the metabolite with MV are used for 
imputation. In the correlation based distance, since metabolites can be highly correlated but 
different in magnitude, the metabolites are first standardized to mean zero and standard 
deviation one before the neighbor selection and then re-scaled back to the original scale after 
imputation (Brock, Shaffer et al. 2008, Tutz and Ramzan 2015) . The distance used to select 
the neighbors is 𝑑𝐶 =  1 − |𝑟|, where 𝑟 is the Pearson correlation. This distance allows for 
information to be incorporated from both positively correlated and negatively correlated 
neighbors.  During the distance calculation MVs are omitted, so that it is based only on the 




The KNN based on the Euclidean (KNN-EU) or Correlation (KNN-CR) distance metrics do 
not account for the truncation at the minimum value or the limit of detection. In our method, 
we propose a modified version of the KNN approach which accounts for the truncation at 
the minimum value called KNN Truncation (KNN-TN).  A truncated distribution occurs 
when there is no ability to know about data that falls below a set threshold or outside a certain 
set range. Often the general idea is to make inference back to the original population and not 
on the truncated population and therefore inference is made on the population mean and not 
the truncated sample mean. In the regular KNN-CR, the metabolites are standardized based 
on the sample mean and sample standard deviation. In KNN-TN, we first estimate the means 
and standard deviation, and use the estimated values for standardizing. Maximum likelihood 
Estimators (MLE) are estimated for the truncated normal distribution. The likelihood for the 
truncated normal distribution is  
𝐿(𝜇, 𝜎2) =  ∏(
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Here a is the truncation point and presumed to be known in our case.  Also note that MVs are 
ignored and the likelihood is based only on the observed data (in essence a partial likelihood 
akin to a Cox regression model (Efron 1977, Ren and Zhou 2010).  The log likelihood is then 
𝑙 = ln 𝐿(𝜇, 𝜎2) 










We use the Newton-Raphson (NR) optimization procedure to find the MLEs for µ and σ 
(Cohen 1949, Cohen 1950) (for details see the Appendix 1). The sample means and standard 
deviations are used as the initial values for the NR optimization. To accelerate the run-time of 
the algorithm, truncation-based estimation of the mean and standard deviation was done only 
on metabolites that had a sample mean within 3 standard deviations of the LOD. For the 
other metabolites, we simply used the sample means and standard deviations. The runtime for 
one dataset with 50 samples and 400 metabolites and the three missing mechanisms was about 
1.20 minutes on average, which included truncation-based estimation of the mean and 
standard deviation and the three imputation methods. In particular for one individual run on 
50 samples and 400 metabolites with 15% missingness, the runtime was about 1.81 seconds 
for the KNN-EU method, 3.41 seconds for the KNN-CR method and 19.95 seconds for the 
KNN-TN method.  The KNN-TN method runtime was a little longer due to the estimation 
of the means and standard deviations.  
Let 𝑦𝑖𝑚 be the intensity of metabolite 𝑚 (1 ≤ 𝑚 ≤ 𝑀) in sample 𝑖 (1 ≤ 𝑖 ≤ 𝑁). The 
following steps outline the KNN imputation algorithms (KNN-TN, KNN-CR, and KNN-
EU):  
1. Choose a K to use for the number of nearest neighbors. 
2. Select the distance metric: Euclidean (KNN-EU) or correlation (KNN-CR and KNN-
TN) 
3. If using correlation metric, decide whether to standardize the data based on sample 
mean and sample standard deviation (KNN-CR) or the truncation-based estimate of 




4. Based on the distance metric and (possibly) standardization, for each metabolite with 
a missing value in sample i find the K closest neighboring metabolites which have an 
observed value in sample i.  
5. For metabolite m with missing value in sample i, calculated the imputed value ?̂?𝑖𝑚 by 
taking the weighted average of the K nearest neighbors for each missing value in the 
metabolite.  The weights are calculated as 𝑤𝑘 =  sign(𝑟𝑘) 𝑑𝑘
−1 ∑ 𝑑𝑙
−1𝐾
𝑙=1⁄ , where 
𝑑1, … , 𝑑𝐾 are the distances between metabolite m and each of the K neighbors and 
𝑟1, … , 𝑟𝐾 are the corresponding Pearson correlations.  The multiplication by sign(𝑟𝑘) 
allows for incorporation of negatively correlated metabolites.  The imputed value is 






6. If using the KNN-CR or KNN-TN approaches, back-transform into the original 
space of the metabolites.  
The steps for the KNN-TN procedure are outlined graphically in Figure 3 (see figure caption 
for detailed explanation).  The graph illustrates the algorithms success at imputing both MAR 






Figure 3: Steps in the KNN-TN imputation algorithm. 
Step 1 (top left panel): The first step in the KNN-TN procedure is to estimate the mean and 
standard deviation of each metabolite.  Here, the distribution and simulated values for 5 
metabolites (M1-M5) and 20 samples are given.  For each metabolite, observed values are 
given by black stars.  Additionally, M2 has 3 values that are MAR (blue stars), while M3 has 5 
points that are MNAR (below the LOD, red stars) and M4 has 2 points below the LOD (red 




dash, while the green horizontal dashed line represents the estimated standard deviation (the 
line extends out +/- 2 standard deviations). 
Step 2 (top right panel):  The second step in the procedure is to transform all the values to 
a common scale, with mean zero and standard deviation of one for each metabolite.  The 
original points are represented in this transformed scale with black stars, with MNAR values 
in red and MAR values in blue. 
Step 3 (bottom left panel):  The next step is to find metabolites with a similar profile on this 
common scale.  In this case, metabolites M1-M3 are highly correlated and M4-M5 are also 
highly correlated.  The two groups of metabolites are also negatively correlated with each 
other, and this information can also be used to aid the imputation process.  The missing values 
are imputed in the transformed space, with weights based on the inverse of the distances 1 −
|𝑟| (𝑟 is the Pearson correlation between the two metabolites).  Contributions from negatively 
correlated metabolites are multiplied by negative one.  The region below the LOD is shaded 
light red. 
Step 4 (bottom right panel): The values are then back-transformed to the original space 
based on the estimated means and standard deviations from Step 1.  Here, we show the three 
metabolites with missing values M2, M3, and M4.  Solid circles represent imputed values for 
MAR (blue circles) and MNAR (red circles).  The region below the LOD is again shaded in 
light red, while the slightly darker shaded regions connect the imputed value with its underlying 
true value.  The imputed values are fairly close to the true values for metabolites M2 and M3, 
while for metabolite M4 the values are further away due to under-estimation of the true 





Assessment of Performance 
We evaluated the performance of the imputation methods by using the root mean squared 
error (RMSE) as the metric. It measures the difference between the estimated values and the 
original true values, when the original true values are known. The following simulation 
procedure from a complete dataset with no MVs is performed. MVs are generated by 
removing a proportion 𝑝 of values from the complete data to generate data with MVs. The 
MVs are then imputed as ?̂?𝑖𝑚 using the given imputation method. Finally, the root mean 
squared error (RMSE) is used to assess the performance by comparing the values of the 
imputed entries with the true values:  
𝑅𝑀𝑆𝐸 =  √
1
𝑛(ℳ) 
∑ (?̂?𝑖𝑚 − 𝑦𝑖𝑚)2
𝑦𝑖𝑚 ∈ ℳ
, 
where ℳ is the set of missing values and 𝑛(ℳ) is the cardinality or number of elements in ℳ.  
Statistical significance of differences in RMSE values between methods was determined using 
multi-factor ANOVA models (with pre-defined contrasts for differences between the 
methods), with main effects for each factor in the simulation study. We further evaluate the 
biological impact of MV imputation on downstream analysis, specifically analyzing differences 
in mean log intensity between groups via the t-test. We evaluate the performances of the MV 
imputation using the metabolite list concordance index (MLCI) (Oh, Kang et al. 2010). By 
applying a selected MV imputation method, one metabolite list is obtained from the complete 
data and another is obtained from the imputed data. The MLCI is defined as:  













where 𝑀𝐶𝐷 is the list of statistically significant metabolites in the complete data, 𝑀𝐼𝐷 is the list 
of statistically significant metabolites in the imputed data, and 𝑀𝐶𝐷
𝐶  and 𝑀𝐼𝐷
𝐶  represent their 
complements, respectively.  The metabolite list taken from the complete dataset is considered 
as the gold standard and a high value in MLCI indicates that the metabolite list from the 
imputed data is similar to that from the complete data.  
2.3 Simulation Studies 
We carried out a simulation study to compare the performance of the three different KNN 
based imputation methods. The simulations were conducted with 100 replications and are 
similar in spirit to those used in Tutz and Ramzan, 2015 (Tutz and Ramzan 2015) . For each 
replication we generated data with different combinations of sample sizes 𝑛 and number of 
metabolites 𝑚. Each set of metabolites for a given sample were drawn from a 𝑚 dimensional 
multivariate normal distribution with a mean vector µ and a correlation matrix Σ. We consider, 
in particular, three structures of the correlation matrix: blockwise positive correlation, 
autoregressive (AR) type correlation and blockwise mixed correlation.  
Blockwise correlation 
Let the columns of the data matrix 𝑌(𝑁 X M),  be divided into 𝐵 blocks, where each block 






The matrices Σ𝑖𝑖 are determined by the pairwise correlations 𝜌𝑤, such that all the components 
have a within block correlation of 𝜌𝑤. The matrices Σ𝑖𝑗 , 𝑖 ≠ 𝑗, are determined by the pairwise 




types of blockwise correlation matrices used in this study are one with all positive correlations 
where the 𝜌𝑤 is positive only and the other is mixed where Σ𝑖𝑖 contains both positive and 
negative correlations. The mixed correlation has the form which is blockwise split in half 
where the diagonal blocks are positively correlated and the off-diagonal blocks are negatively 



























where the + is the positive 𝜌𝑤 and − is the negative 𝜌𝑤 
Autoregressive-type correlation 
The other correlation structure used is the autoregressive type correlation. An AR correlation 
matrix of order one is defined by pairwise correlations 𝜌|𝑖−𝑗|, for metabolites𝑖, 𝑗 = 1,… ,𝑀.  
The combinations used were (𝑁 [Samples] X 𝑀 [Metabolites]) =  20 X 400, 50 X 400,
and 100 X 900. The means of the metabolites are assumed to be different and are generated 
from a Uniform(−5,5) distribution. The metabolites within each block were strongly 
correlated with 𝜌𝑤 = 0.7, but nearly uncorrelated with metabolites in other blocks,  𝜌off =
0.2. In the AR type correlation 𝜌 = 0.9. For the degree of missing, three levels were studied: 
9% missing, 15% missing and 30% missing. Missing data were created based on the two kinds 
of missingness, MNAR and MAR (technically the latter are generated by MCAR, though a 
MAR mechanism can be exploited for imputation since the metabolite values are highly 
correlated). Within each level of missing, a one-third and two-third combination was used to 




and vice versa. For example in 9% missing, we considered 6% as MNAR and 3% as MAR and 
then considered 6% as MAR and 3% as MNAR. Data below the given MNAR percent was 
considered as missing and the MAR percent was randomly generated in the non-missing data. 
The datasets with missing values were passed through a cleaning process where metabolites 
with more than 75% missing observations were eliminated individually. Throughout, the 
number of neighbors K used for imputation was set to 10. We evaluated three K’s (K=5, 10 
and 20) and found consistency in K=10 as it gave the best RMSE values. 
2.4 Real Data Studies 
Myocardial Infarction Data 
We used the in vivo metabolomics data on myocardial infarction (MI). The data consists of 
two groups, MI vs control, 5 samples in each group and 288 metabolites. Adult mice were 
subjected to permanent coronary occlusion (myocardial infarction; MI) or Sham surgery. Adult 
C57BL/6J mice from The Jackson Laboratory (Bar Harbor, ME) were used in this study and 
were anesthetized with ketamine (50 mg/kg, intra-peritoneal) and pentobarbital (50 mg/kg, 
intra-peritoneal), orally intubated with polyethylene-60 tubing, and ventilated (Harvard 
Apparatus Rodent Ventilator, model 845) with oxygen supplementation prior to the 
myocardial infarction. The study was aimed to examine the metabolic changes that occur in 
the heart in vivo during heart failure using mouse models of permanent coronary ligation. A 
combination of liquid chromatography (LC) MS/MS and gas chromatography (GC) MS 
techniques was used to measure the 288 metabolites in these hearts. The MS was based on a 
Waters ACQUITY UPLC and a Thermo-Finnigan LTQ mass spectrometer, which consisted 
of an electrospray ionization source and linear ion trap mass analyzer. The cases had 220 




4.8% missing values whereas the controls had 241 metabolites with complete values, 7 
metabolites with complete missing and 40 metabolites had 7.8% missing values. The LOD for 
this dataset is considered as the minimum value of the dataset as commonly used in untargeted 
metabolomics. Details of the experiments are described in Sansbury et al (Sansbury, 
DeMartino et al. 2014).   
Atherothrombotic Data 
We used the human atherothrombotic myocardial infarction (MI) metabolomics data. The 
data was identified between two groups, those with acute MI and those with stable coronary 
artery disease (CAD). Acute MI was further stratified into thrombotic (Type1) and non-
thrombotic (Type2) MI. The data was collected across four time points and for the context of 
this research we used the baseline data only. The three groups, sCAD, Type1 and Type2 had 
15, 11, and 12 patients with 1032 metabolites. The sCAD had 685 metabolites with complete 
values, 39 metabolites with complete missing, and 308 metabolites had 10.2% missing, the 
Type1 group had 689 metabolites with complete values, 43 metabolites with complete missing 
and 300 metabolites had 9.8% missing whereas the Type2 group had 610 metabolites with 
complete values, 66 metabolites with complete missing and 356 metabolites had 12.3% 
missing. The LOD for this dataset is considered as the minimum value of the dataset as 
commonly used in untargeted metabolomics. Plasma samples collected from the patients were 
used and 1032 metabolites were detected and quantified by GC-MS and ultra-performance 
(UP) LC-MS in both positive and negative ionization modes. Details of the experiment are 
described in DeFilippis et al (DeFilippis, Chernyavskiy et al. 2016). 




We used the African Studies data which is publicly available on The Metabolomics 
WorkBench. This data is available at the NIH Common Fund's Data Repository and 
Coordinating Center (supported by NIH grant, U01-DK097430) website 
(http://www.metabolomicsworkbench.org), where it has been assigned a Metabolomics 
Workbench Project ID: PR000010. The data is directly accessible from The Metabolomics 
WorkBench database .  The data was collected to compare metabolomics, phenotypic and 
genetic diversity across various groups of Africans. The data consisted of 40 samples; 25 
samples from Ethiopia and 15 samples from Tanzania and 5126 metabolites. For the purpose 
of this study we made sure we had a complete dataset in order to compare the methods. The 
complete datasets created were two datasets based on the country; Ethiopia dataset (25 
samples by 1251 metabolites) and Tanzania dataset (15 samples by 2250 metabolites).  
Due to small sample sizes in metabolomics datasets, we used a simulation approach originally 
designed to resemble the multivariate distribution of gene expression in the original microarray 
data (Parrish, Spencer Iii et al. 2009). Since our Myocardial Infarction and Atherothrombotic 
data had missing values we first imputed missing values based on the KNN-CR method and 
then used the simulation method to simulate 100 datasets. For the African Race data we started 
with a complete dataset. The different groups were considered as independent datasets and 
the imputation was done on them separately. We used the similar mechanism for missingness 
and screening as used in the simulation studies, with sample sizes of 25 and 50 for the 
myocardial infarction dataset, 50 and 100 for the human atherothrombotic dataset and 15 and 






In this section, we present the results of the simulation studies comparing the performance 
measures of KNN-TN, KNN-CR and KNN-EU. Figures 4, 5 and 6 plot the distribution of 
the RMSE values for KNN-TN, KNN-CR and KNN-EU by correlation type and percent 
missing for sample sizes 20, 50, and 100, respectively. Tables 1, 2 and 3 show the average 
RMSE results of the different simulation settings based on the 100 replications. Since the 
pattern of results was similar regardless of whether the percent MNAR was less than the 
percent MAR, results are shown for percent MNAR > percent MAR only.  As can be seen 
from the tables and figures, the results consistently show that the KNN-TN method 
outperforms both the KNN-CR and KNN-EU methods. ANOVA modeling of the RMSE 
values shows statistically significant differences between the KNN-TN method and KNN-CR 
/ KNN-EU methods for all three cases, and significant effects for the other two factors 
(percent missing and correlation type) as well (Tables 4-6).  To visualize how our method 
works we selected a simulated dataset from N = 50 and M = 400 with 15% missing (10% 
below the LOD and 5% MAR) and compared the true missing values with KNN-TN, KNN-
CR and KNN-EU. Figure 7 demonstrates that our imputation method imputes values below 
the limit of detection whereas the Euclidean or correlation based metrics are less accurate for 
these values. The figure is reproducible with our included example script in Supplemental File 
5.  We further compared the three methods with standard imputation methods in 
metabolomics (zero, minimum and mean imputation methods) and all three KNN imputation 
algorithms outperformed the standard methods. The results for the simulation studies are 





Figure 4:  Boxplots of root mean squared error for KNN-TN, KNN-CR and KNN-EU for 
100 datasets, 20 samples by 400 metabolites.  
Total missing was considered at 9%, 15% and 30% and within each missing MNAR is greater 
than MAR. The three correlation structure used was i) only positive correlation 0.7, ii) AR(1) 





Figure 5: Boxplots of root mean squared error for KNN-TN, KNN-CR and KNN-EU for 
100 datasets, 50 samples by 400 metabolites. 
Total missing was considered at 9%, 15% and 30% and within each missing MNAR is greater 
than MAR. The three correlation structure used was i) only positive correlation 0.7, ii) AR(1) 





Figure 6: Boxplots of root mean squared error for KNN-TN, KNN-CR and KNN-EU for 
100 datasets, 100 samples by 900 metabolites 
 Total missing was considered at 9%, 15% and 30% and within each missing MNAR is 
greater than MAR. The three correlation structure used was i) only positive correlation 0.7, 





Figure 7:  Comparison of the true missing values with missing values imputed from the three 
methods based on a single simulated dataset (N = 50 X M = 400).  
The values for the first 20 metabolites are shown. The x-axis represents the metabolites, and 
the y-axis represents the intensity values. The open black circles represent observed values, 
while the black stars represent missing observations.  Blue triangles, red squares, and green 




respectively. The region below the LOD is shaded in light red.  In most cases, the KNN-TN 
algorithm is able to impute missing values below the LOD better than the other two methods 
(e.g., metabolites 1, 3, 4, 7, 8, 12, and 13).  In other cases, the KNN-TN imputations are similar 
to KNN-CR (e.g. for metabolite 5, for which the missing below the LOD was too high and 
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Table 1: Average RMSE of 100 datasets, 20 samples by 400 metabolites for KNN-TN, 
KNN-CR and KNN-EU.  
Total missing was considered at 9%, 15% and 30%, and within each missing, MNAR was 





MNAR/MAR DATA CORR KNN-TN KNN-CR KNN-EU 























































Table 2: Average RMSE of 100 datasets, 50 samples by 400 metabolites for KNN-TN, KNN-
CR and KNN-EU. 
Total missing was considered at 9%, 15% and 30%, and within each missing, MNAR was 
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Table 3: Average RMSE of 100 datasets, 100 samples by 900 metabolites for KNN-TN, KNN-
CR and KNN-EU.  
Total missing was considered at 9%, 15% and 30%, and within each missing, MNAR was 





Table 4: Specific differences in RMSE for the imputation methods and ANOVA results for 
the factors for 20 samples by 400 metabolites. 
Contrast Estimate Std. Error t Value P Value 
KNN-CR – KNN-TN 0.094 0.002815 33.303 <2e-16 *** 
KNN-EU – KNN-TN 0.224 0.002815 79.519 <2e-16 *** 
 
Table 4 a. Specific differences in RMSE values for the KNN-CR and KNN-EU methods 
compared to the KNN-TR method for 20 samples by 400 metabolites. 
 Df Sum Sq Mean Sq F value  P Value 
Imputation Method 2 22.752 11.376 3189.4 <2e-16 *** 
Percent Missing  2 6.574 3.287 921.6 <2e-16 *** 
Correlation Type 2 12.333 6.166 1728.8 <2e-16 *** 
Residuals 2693 9.605 0.004   
 
Table 4 b. ANOVA table giving the significance of the three factors in the simulation study 






Table 5: Specific differences in RMSE for the imputation methods and ANOVA results for 
the factors for 50 samples by 400 metabolites. 
 Estimate Std. Error t Value P Value 
KNN-CR – KNN-TN 0.148 0.002517 58.72 <2e-16 *** 
KNN-EU – KNN-TN 0.224 0.002517 163.23 <2e-16 *** 
 
Table 5 a. Specific differences in RMSE values for the KNN-CR and KNN-EU methods 
compared to the KNN-TR method for 50 samples by 400 metabolites.  
 Df Sum Sq Mean Sq F value  P Value 
Imputation Method 2 77.95 38.98 13672 <2e-16 *** 
Percent Missing  2 5.83 2.92 1023 <2e-16 *** 
Correlation Type 2 9.71 4.85 1703 <2e-16 *** 
Residuals 2693 7.68 0.00   
 
Table 5 b. ANOVA table giving the significance of the three factors in the simulation study 





Table 6: Specific differences in RMSE for the imputation methods and ANOVA results for 
the factors for 100 samples by 900 metabolites. 
 Estimate Std. Error t Value P Value 
KNN-CR – KNN-TN 0.186 0.002278 81.60 <2e-16 *** 
KNN-EU – KNN-TN 0.473 0.002278 207.60 <2e-16 *** 
 
Table 6 a. Specific differences in RMSE values for the KNN-CR and KNN-EU methods 
compared to the KNN-TR method for 100 samples by 900 metabolites.  
 Df Sum Sq Mean Sq F value  P Value 
Imputation Method 2 102.18 51.09 21877 <2e-16 *** 
Percent Missing  2 6.55 3.27 1402 <2e-16 *** 
Correlation Type 2 5.35 2.67 1145 <2e-16 *** 
Residuals 2693 6.29 0.00   
 
Table 6 b. ANOVA table giving the significance of the three factors in the simulation study 
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Table 7: Average RMSE of 100 datasets, 20 samples by 400 metabolites for zero, minimum 
and mean imputation methods.  
Total missing was considered at 9%, 15% and 30%, and within each missing, MNAR was 





MNAR/MAR DATA CORR Zero Min Mean 























































Table 8: Average RMSE of 100 datasets, 50 samples by 400 metabolites for zero, minimum 
and mean imputation methods.  
Total missing was considered at 9%, 15% and 30%, and within each missing, MNAR was 





MNAR/MAR DATA CORR Zero Min Mean 























































Table 9: Average RMSE of 100 datasets, 100 samples by 900 metabolites for zero, minimum 
and mean imputation methods.  
Total missing was considered at 9%, 15% and 30%, and within each missing, MNAR was 




Real Data Simulations Results 
We conducted a simulation study based on the real datasets to further validate our results. 
Table 10, 11, and 12 show the results of the in vivo myocardial infarction data, human 
atherothrombotic data, and publicly available African Race data.  In all cases the KNN-TN 
and KNN-CR results are substantially better than the KNN-EU results, with RMSE means 
more than two standard deviations below the means for KNN-EU (p-value < 0.05 for 
KNN-TN vs. KNN-EU contrast, Tables 13 - 15).  The difference between KNN-TN and 
KNN-CR is much smaller by comparison, with statistically significant differences only for 
the Atherothrombotic and African Race data sets.  However, in every case the mean RMSE 
for KNN-TN is below that for KNN-CR. Tables 13 – 15 show that significant differences in 
RMSE values exist according to the other factors in the simulation study (percent missing, 
group, and sample size) as well.  We further compared the three methods the standard 
imputation methods in metabolomics (zero, minimum and mean imputation methods) and 
all three KNN imputation algorithms outperformed the standard methods. The results for 
the real data are shown in Tables 16-18 where we see the average RMSE range was from 2.2 
to 7.2. The t-test analysis and the MLCI values are shown in Table 4. A higher value of 
MLCI indicates that the metabolite list from the imputed data is similar to that from the 
complete data and from the tables KNN-TN and KNN-CR have the highest values, whereas 
the KNN-EU, Zero, Minimum and Mean imputation methods have lower MLCI indexes.  
Differences in mean MLCI values between KNN-TN and KNN-CR were not statistically 
significant (Tables 19-21), whereas KNN-TN was significantly better than the other four 
methods in all cases except for the African Race data (where mean imputation and all KNN 
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Table 10:  Average RMSE of 100 simulations using the in vivo myocardial infarction dataset 
for KNN-TN, KNN-CR and KNN-EU.  
Total missing was considered at 9%, 15% and 30%, and within each missing, MNAR was 







GROUP KNN-TN KNN-CR KNN-EU 


































































































































Table 11: Average RMSE of 100 simulations using the human atherothrombotic dataset for 
KNN-TN, KNN-CR and KNN-EU.  
Total missing was considered at 9%, 15% and 30%, and within each missing, MNAR was 







DATASET KNN-TN KNN-CR KNN-EU 











































Table 12: Average RMSE of 100 simulations using the African Race dataset for KNN-TN, 
KNN-CR and KNN-EU. 
Total missing was considered at 9%, 15% and 30%, and within each missing, MNAR was 





Table 13: Specific differences in RMSE for the imputation methods and ANOVA results for 
the factors for Myocardial dataset. 
 Estimate Std. Error t Value P Value 
KNN-CR – KNN-TN 0.005 0.00275 1.737 0.0825 
KNN-EU – KNN-TN 0.152 0.00275 55.333 <2e-16 *** 
 
Table 13 a. Specific differences in RMSE values for the KNN-CR and KNN-EU methods 
compared to the KNN-TR method for Myocardial dataset.  
 Df Sum Sq Mean Sq F value  P Value 
Imputation Method 2 17.95 8.98 1979.08 <2e-16 *** 
Percent Missing  2 1.88 0.94 207.76 <2e-16 *** 
Group 1 37.82 37.82 8339.65 <2e-16 *** 
Sample Size 1 0.14 0.14 31.56 2.08e-08 
Residuals 3593 16.30 0.00   
 






Table 14: Specific differences in RMSE for the imputation methods and ANOVA results for 
the factors for Atherothrombotic dataset. 
 Estimate Std. Error t Value P Value 
KNN-CR – KNN-TN 0.019 0.00239 479.375 <2e-16 *** 
KNN-EU – KNN-TN 0.240 0.00207 9.261 <2e-16 *** 
 
Table 14 a. Specific differences in RMSE values for the KNN-CR and KNN-EU methods 
compared to the KNN-TR method for Atherothrombotic dataset.  
 Df Sum Sq Mean Sq F value  P Value 
Imputation Method 2 64.25 32.13 8330.9 <2e-16 *** 
Percent Missing  2 1.65 0.82 213.6 <2e-16 *** 
Group 2 27.07 13.54 3510.5 <2e-16 *** 
Sample Size 1 5.99 5.99 1554.0 <2e-16 *** 
Residuals 5392 20.79 0.00   
 






Table 15: Specific differences in RMSE for the imputation methods and ANOVA results for 
the factors for African Race dataset. 
 Estimate Std. Error t Value P Value 
KNN-CR – KNN-TN 0.015 0.002532 5.941 3.4e-09 *** 
KNN-EU – KNN-TN 0.087 0.002532 34.523 <2e-16 *** 
 
Table 15 a. Specific differences in RMSE values for the KNN-CR and KNN-EU methods 
compared to the KNN-TR method for African Race dataset. 
 Df Sum Sq Mean Sq F value  P Value 
Imputation Method 2 2.621 1.3103 681.4 <2e-16 *** 
Percent Missing  2 3.478 1.7388 904.2 <2e-16 *** 
Group 1 3.054 3.054 1588.2 <2e-16 *** 
Residuals 1794 3.450    
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Table 16:  Average RMSE of 100 simulations using the in vivo myocardial infarction dataset 
for zero, minimum and mean imputation methods.  
Total missing was considered at 9%, 15% and 30%, and within each missing, MNAR was 







GROUP Zero Min Mean 


































































































































Table 17:  Average RMSE of 100 simulations using the human atherothrombotic dataset for 
zero, minimum and mean imputation methods.  
Total missing was considered at 9%, 15% and 30%, and within each missing, MNAR was 
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Table 18: Average RMSE of 100 simulations using the African Race dataset for zero, minimum 
and mean imputation methods.  
Total missing was considered at 9%, 15% and 30%, and within each missing, MNAR was 





Table 19: Specific differences in MLCI for the imputation methods and ANOVA results for 
the factors for Myocardial Infarction dataset. 
Contrast Estimate Std. Error t Value P Value 
Zero – KNN-TN -0.511 0.0046 -96.82 <2e-16 *** 
Min – KNN-TN -0.152 0.00527 -28.75 <2e-16 *** 
Mean – KNN-TN -0.038 0.00527 -7.23 5.8e-13 
KNN-CR – KNN-TN -0.002 0.00527 -0.41 0.679 
KNN-EU – KNN-TN -0.024 0.00527 -4.42 1.03e-05 
 
Table 19 a. Specific differences in MLCI values for the Zero, minimum, mean, KNN-CR and 
KNN-EU methods compared to the KNN-TR method for the Myocardial Infarction data.  
 Df Sum Sq Mean Sq F value  P Value 
Imputation Method 5 118.71 23.742 2846.5 <2e-16 *** 
Percent Missing  2 8.81 4.407 528.4 <2e-16 *** 
Sample Size 1 3.18 3.178 381.0 <2e-16 *** 
Residuals 3591 29.95 0.008   
 
Table 19 b. ANOVA table giving the significance of the three factors in the simulation study 





Table 20: Specific differences in MLCI for the imputation methods and ANOVA results for 
the factors for Atherothrombotic dataset. 
Contrast Estimate Std. Error t Value P Value 
Zero – KNN-TN -0.295 0.0044 .-58.47 <2e-16 *** 
Min – KNN-TN -0.112 0.0050 -22.12 <2e-16 *** 
Mean – KNN-TN -0.036 0.0050 -7.17 8.9e-13 
KNN-CR – KNN-TN -0.001 0.0050 0.25 0.803 
KNN-EU – KNN-TN -0.017 0.0050 -3.36 0.0008 
 
Table 20 a. Specific differences in MLCI values for the Zero, minimum, mean, KNN-CR and 
KNN-EU methods compared to the KNN-TR method for the Atherothrombotic data.  
 Df Sum Sq Mean Sq F value  P Value 
Imputation Method 5 39.67 7.93 1037.9 <2e-16 *** 
Percent Missing  2 2.08 1.04 136.1 <2e-16 *** 
Sample Size 1 3.10 3.10 405.0 <2e-16 *** 
Residuals 3591 27.45 0.01   
 
Table 20 b. ANOVA table giving the significance of the three factors in the simulation study 





Table 21: Specific differences in MLCI for the imputation methods and ANOVA results for 
the factors for African Race dataset. 
Contrast Estimate Std. Error t Value P Value 
Zero – KNN-TN -0.239 0.0080 -24.523 <2e-16 *** 
Min – KNN-TN -0.139 0.0097 -14.214 <2e-16 *** 
Mean – KNN-TN -0.008 0.0097 -0.849 0.396 
KNN-CR – KNN-TN -0.001 0.0097 0.052 0.958 
KNN-EU – KNN-TN -0.003 0.0097 -0.262 0.795 
 
Table 21 a. Specific differences in MLCI values for the Zero, minimum, mean, KNN-CR and 
KNN-EU methods compared to the KNN-TR method for the African Race data.  
 Df Sum Sq Mean Sq F value  P Value 
Imputation Method 5 15.39 3.079 216.1 <2e-16 *** 
Percent Missing  2 1.06 0.530 37.2 <2e-16 *** 
Residuals 1792 25.53 0.014   
 
Table 21 b. ANOVA table giving the significance of the three factors in the simulation study 






The objective of this study was to develop an approach for imputing missing values in data 
generated by mass spectrometry.  When metabolites occur at low abundance, below the 
detection limit of the instrumentation, we can consider it as missing not at random. In contrast, 
missing values resulting from technical errors are considered missing at random.  To this end, 
we introduce an extension to the KNN imputation algorithm which handles truncated data, 
termed KNN-TN.  To our knowledge, this is the first proposal approach which can 
simultaneously handle missing data generated by both MNAR (falling below the LOD) and 
MAR mechanisms.  Since MNAR is involved and is due to the detection limit, we consider 
the detection limit as a truncation point and assume that the metabolite follows a truncated 
normal distribution. Therefore the mean and standard deviation are estimated from the 
truncated normal distribution and used to standardize the metabolites in the KNN imputation 
algorithm. The simulation results show that the proposed method performs better than KNN 
based on correlation or Euclidean measures when there is missing data due to a threshold 
LOD.  
In our simulations we evaluated three different data set sizes: small (20 samples by 400 
metabolites), medium (50 samples by 400 metabolites) and large (100 samples by 900 
metabolites).  As the sample size increased, the RMSE was lower for the different missing 
percentages. The LOD was calculated based on the missing percentage. For instance in 9% 
missing (where 6% was considered as MNAR) the 6% quantile for the complete data was 
considered as the LOD where we considered everything below that value as missing.  For the 
simulation studies, the results shown in the tables are based on when the MNAR percentage 
is greater than the MAR percentage (e.g. for 9% total missing, 6% is MNAR and 3% is MAR). 




percentage, with KNN-TN outperforming both KNN-CR and KNN-EU. In our results, 
when MNAR is greater than MAR we typically observed the RMSE was greatest at 15% MVs 
whereas it was lowest at 30% MVs. This counter-intuitive result is likely due to the fact that in 
the cleaning process (which removes metabolites with >75% MVs) we are removing more 
metabolites whose values are concentrated near the LOD. For example in the case of 50 
samples by 400 metabolites, after screening we reduced the metabolites to an average of about 
387 metabolites for 15% missing and 345 metabolites for 30% missing.  When the MAR was 
greater than MNAR, the RMSE increased with the increase in MV percentage.  
Troyanskaya et al. (Troyanskaya, Cantor et al. 2001) evaluated a number of different missing 
value imputation methods and suggested the KNN method to be more robust and sensitive 
compared to the other methods. In another study by Brock et al (Brock, Shaffer et al. 2008), 
they compared the KNN based on two different neighbor selection metrics, Euclidean and 
Correlation and concluded that the correlation based neighbor selection performed better than 
the Euclidean neighbor selection in most of the cases.  In this study we focused on enhancing 
the KNN method specifically for imputing values when there is missing due to an LOD.  
Future studies will evaluate how these methods compare to other imputation algorithms in 
this setting.  
Recently, several studies have investigated imputation for MS data (Hrydziuszko and Viant 
2011, Gromski, Xu et al. 2014, Taylor, Ruhaak et al. 2016). Taylor et al. (Taylor, Ruhaak et al. 
2016) evaluated seven different imputation methods (half minimum, mean, KNN, local least 
squares regression, Bayesian principal components analysis, singular value decomposition and 
random forest) and its effects on multiple biological matrix analyses, more specifically on the 




MANOVA results. They concluded that no imputation method was superior but the mean 
and half minimum performed poorly. Gromski et al (Gromski, Xu et al. 2014) looked at five 
different imputation methods (zero, mean, median, KNN and random forest) and its influence 
on unsupervised and supervised learning. Their results recommended that random forest is 
better than the other imputation methods and it provided better results in terms of 
classification rates for both principal components-linear discriminant analysis and partial least 
squares-discriminant analysis. Hrydziuszko et al. (Hrydziuszko and Viant 2011) suggested the 
need of missing value imputation as an important step in the processing pipeline. They used 
metabolomics datasets based on infusion Fourier transform ion cyclotron resonance mass 
spectrometry and compared eight different imputation methods (predefined value, half 
minimum, mean, median, KNN, Bayesian Principal Component Analysis, Multivariate 
Imputation, and REP). Based on their findings, KNN performed better than the other 
methods.   
We included a preliminary investigation of the impact of MV imputation on downstream 
statistical analysis of metabolomics data.  While the KNN-TN method was significantly better 
than four other imputation algorithms (zero imputation, minimum value imputation, and 
KNN-EU imputation) in two of three data sets, it was no better than KNN-EU imputation.  
Further, on the African Race data set there was no significant difference between any of the 
KNN imputation algorithms and mean imputation, though all were better than zero and 
minimum value imputation. Although this result is somewhat disappointing, a more 
comprehensive study of all potential downstream analyses is needed to fully determine, 
whether the improved imputation accuracy of the KNN-TN method translates into better 
downstream statistical analysis, and the characteristics of data sets for which more advanced 




In some cases (high percent missing or small sample size) the variability of the RMSE for 
KNN-TN is higher than or similar to that for KNN-CR. This is directly related to the 
estimation of the mean and variance for the truncated normal distribution, which can be 
difficult when there are excessive amounts of missing data.  In fact, for sample sizes less than 
20 there is little to no gain in using KNN-TN over KNN-CR, unless the missing percentage 
is below the values evaluated in this study (data not shown).  To stabilize the estimation of 
these parameters, one possibility is to again borrow information from metabolites having 
similar intensity profiles.  This is akin to the empirical Bayes approach used to fit linear models 
and generalized linear models in microarray and RNA-seq studies (Smyth , Smyth 2005, 
Robinson, McCarthy et al. 2010, Anders and Huber 2012).   Our future research will explore 
this possibility for improving the KNN-TN algorithm.    
A related limitation is the reliance on the normality assumption for estimating the truncated 
mean and standard deviation. In our simulation study we investigated data from a normal 
distribution, whereas in many cases metabolite data will be non-normally distributed. In these 
cases we suggest to first transform the data to normality, then impute the values and lastly 
transform back. As seen in our real datasets, the metabolites are not normally distributed and 
we log transform them to approximately achieve normality prior to imputation.  
The likelihood used in our KNN-TN method is based solely on the observed metabolite data.  
The full data likelihood would include missing data as well.  This is difficult to specify in the 
current situation as the mechanism by which the MVs were generated (e.g., MNAR, MAR, or 
MCAR) is unknown.  It is possible to improve the algorithm by incorporating these MVs 




determined to be neighbors) is necessary to inform the system regarding the missingness 
mechanism (e.g., via the EM-algorithm). 
2.7 Conclusions 
In conclusion, the experimental results reveal that compared with KNN based on correlation 
and Euclidean metrics, KNN based on truncation estimation is a competitive approach for 
imputing high dimensional data where there is potential missingness due to a truncation 
(detection) threshold. Results based on both real and simulated experimental data show that 
the proposed method (KNN-TN) generally has lower RMSE values compared to the other 
two KNN methods and simpler imputation algorithms (zero, mean, and minimum value 
imputation) when there is both missing at random and missing due to a threshold value.  
Assessment based on concordance in statistical significance testing demonstrate that KNN-
TN and KNN-CR are roughly equivalent and generally outperform the other four methods.  
However, the approach has limitations with smaller sample sizes, unless the missing 
percentage is also small. Lastly, even though this study is based on metabolomic datasets our 
findings are more generally applicable to high-dimensional data that contains missing values 
associated with an LOD, for instance proteomics data and  delta-CT values from qRT-PCR 








BAYESIAN APPROACH FOR IMPUTATION OF MISSING VALUES 
WITH APPLICATION TO HIGH DIMENSIONAL DATA WITH 
DETECTION LIMIT THRESHOLD 
 
3.1 Background 
In many typical high throughput studies, a large number of features 
(genes/proteins/transcriptomes/metabolites) are measured quantitatively from biological 
samples, e.g. from humans or animals. Metabolomics is the most downstream field in the 
omics cascade and provides vital information about metabolic pathways and significant 
biomarkers related to a certain phenotype. Since metabolites are downstream products, they 
are very sensitive to various biological states, and can potentially be more readily used for early 
disease detection than other molecular information, as well as provide contemporaneous 
information for a variety of other studies (Xi et al 2015). In most MS studies, the number of 
features (𝑝) is much larger than the number of samples (𝑛). Because of this large 𝑝 and 
small 𝑛, one of the obstacles is to avoid over-fitting the data. Bayesian methods have become 
widespread in numerous scientific fields, and this rapid rise in popularity is partially attributable 
to the decrease in the cost of computational assets that are needed to estimate more complex 
models (Daniel 2016, Dunson, 2001). There have been several Monte Carlo simulation studies 
and recent methodologies that have illustrated the benefits of Bayesian methods over 




& van de Schoot, 2015, Depaoli and Clifton Dunson, 2000, McNeish & Stapleton, 2016). 
Bayesian statistics is used mainly when complex models cannot be estimated using 
conventional statistics (Depaoli and Schoot 2016), and many complex models require Bayesian 
methods to improve convergence problems (Depaoli & Clifton, 2015). It is not necessarily 
based on large samples and can produce practical results with moderate to small samples, 
especially when strong prior information is available. Also with the prior distribution, one can 
utilize the un(certainty) about a parameter and update this knowledge (Depaoli and Schoot 
2016).  
Many studies have noted the use of Bayesian methods over frequentist methods to better 
accommodate small sample sizes due to the promise of not using sample size adjustments 
(Doron & Gaudreau, 2014, Kliem, Kröger, & Kosfelder, 2010, Stenling, Ivarsson, Johnson, & 
Lindwall, 2015). Consistency and asymptotic normality are necessary properties for inference 
based on the Maximum Likelihood (ML) estimation, a common frequentist approach. These 
properties require large sample sizes, and thus, ML estimates in smaller sample sizes can be 
quite poor (Lee & Song, 2004; McNeish & Stapleton, 2014).  
In this work, we develop a Bayesian model for imputing missing values with small sample 
sizes. The model is based on data augmentation, a common estimation technique in missing 
value problems (Tanner and Wong 1987). It has been widely used as an alternative to the EM 
algorithm (Dempster et al 1977) and maximum likelihood estimation. The most commonly 
used approach for fitting hierarchical models to data is based on the Bayesian paradigm (Lele 
et al, 2007, Link et al 2002, Clark 2005, Clark and Gelfand 2006). Computing the Bayesian 




Carlo (MCMC) algorithms (Lele et al 2007). We develop an MCMC algorithm to estimate the 
posterior distribution of the parameters in our models.  
3.2 Methods 
We develop a Bayesian model and MCMC algorithm for estimating the posterior distribution 
of the parameters in our model via a Gibbs sampler. The idea in Gibbs sampling is to generate 
posterior samples by sweeping through each variable (or block of variables) to sample from 
its conditional distribution with the remaining variables fixed to their current values. The 
algorithm below shows the general framework for the Gibbs sampler.  
Gibbs sampler algorithm  
Intialize 𝑥(0) ~ 𝑞(𝑥) 
for iteration 𝑖 = 1,2, … ,𝑀 DO 
𝑥1
(𝑖)
 ~ 𝑝(𝑋1 = 𝑥1|𝑋2 = 𝑥2
(𝑖−1), 𝑋3 = 𝑥3




 ~ 𝑝(𝑋2 = 𝑥2|𝑋1 = 𝑥1
(𝑖), 𝑋3 = 𝑥3
(𝑖−1), … , 𝑋𝑁 = 𝑥𝑁
(𝑖−1)) 
   … 
𝑥𝑁
(𝑖)
 ~ 𝑝(𝑋𝑁 = 𝑥𝑁|𝑋1 = 𝑥1
(𝑖), 𝑋2 = 𝑥2
(𝑖), … , 𝑋𝑁−1 = 𝑥𝑁−1
(𝑖) ) 
End iteration 
This process continues until convergence is attained, and the sampling is not done directly 
from the full posterior distribution but rather sweeping through all the posterior conditionals, 
one variable block at a time. MCMC algorithms are typically run for a large number of 
iterations assuming convergence to the target posterior is achieved. The theory of MCMC 
guarantees that the stationary distribution of the samples generated is the target joint posterior 
that we are interested in. Due to the impact of initial values, the samples simulated based on 




distribution. It is common to discard these early samples, and the discarded iterations are often 
referred to as the “burn-in” period. However, there are several limitations to Gibbs sampling. 
First, even if we have the full posterior joint density function, it may not be possible to derive 
the conditionals for each variable in the model. Secondly, if we have the posterior conditionals 
for each variable, it might be that they are not a known form, and therefore, there is not a 
direct method to generate samples. The Metropolis-Hastings (MH) algorithm simulates 
samples from a probability distribution by making use of the full joint density function and a 
proposal distribution for each variable of interest. Unlike Gibbs samples, the MH algorithm 
doesn’t require the ability of generating samples from all the full conditional distributions, but 
a proposal or candidate distribution is chosen given the current value of the random variables. 
The algorithms below shows the general framework for the MH algorithm. 
Metropolis-Hastings algorithm 
Initialize 𝑥(0) ~ 𝑞(𝑥) 
for iteration 𝑖 = 1,2, … ,𝑀 DO 
   Propose: 𝑥𝑐𝑎𝑛𝑑~𝑞 (𝑥𝑖| 𝑥(𝑖−1)) 
   Acceptance Probability: 




   𝑢 ~ Uniform(𝑢;  0,1) 
   if 𝑢 <  𝛼 then 
 Accept the proposal: 𝑥(𝑖) = 𝑥𝑐𝑎𝑛𝑑 
   else 
   Reject the proposal: 𝑥(𝑖) = 𝑥(𝑖−1) 
   end if 





The Bayesian paradigm historically has been proven to stabilize parameter estimation by 
borrowing information available from similar features (/ proteins/metabolites). Let 
𝑌𝑖 ~ 𝑁(𝑋𝑖𝛽, Σ), where 𝑌𝑖𝑗 is the intensity of metabolite 𝑗 (1 ≤ 𝑗 ≤ 𝑀) in the sample 
𝑖 (1 ≤ 𝑖 ≤ 𝑁) and 𝑋𝑖 is the design matrix for the sample. The vector of the mean parameters 
𝛽 will contain the mean value of each metabolite, as well as group/treatment differences as 
determined by the design matrix. As M is much larger than N, we adopt a lower-dimensional 
structure on the covariance matrix Σ with autoregressive correlation structure. The Σ is a 
function of 𝑝 + 1 parameters having a structured form Σ =  Σ (𝜎1
2, … , 𝜎𝑀
2 , 𝜌). We develop a 
robust approach which allows for both MVs due to MNAR (missing below the LOD 
threshold 𝜉) and MAR (missing for a different reason). The MNAR framework requires 
specification of the missing data mechanism (MDM). Letting 𝑅𝑖𝑗 be equal to 0 if 𝑌𝑖𝑗 is missing 
and 1 if 𝑌𝑖𝑗 is observed, our MDM has the form  
 Pr(𝑅𝑖𝑗 = 0 |𝑌𝑖𝑗) = {
𝛼, 𝑌𝑖𝑗 > 𝜉
1, 𝑌𝑖𝑗 ≤ 𝜉
  . 
If the value of 𝑌𝑖𝑗 is less than the threshold, it will always be seen to as missing (due to MNAR), 
and if 𝑌𝑖𝑗 > 𝜉, then 𝑌𝑖𝑗 may be missing with probability 𝛼 (due to MAR). We use non-
informative priors. A conjugate normal prior with large variance for the regression 
coefficients 𝛽 is used, along with a hierarchical structure for the metabolite-specific variances 
to allow sharing across metabolites and stabilization of estimates. The priors for the 
parameters are as follows:  
 𝛼 ~ Uniform (0,1) 





2)~ Normal (𝜆1, 𝜆2) 
 𝜆1~ Normal (a, b) 
 𝜆2~ Inv Gamma (c, d) 
 𝜌 ~ Uniform (0,1) 
Combining the data likelihood, MDM and prior distributions, the full joint density is 
proportional to  
 𝑃(𝑅𝑖𝑗 , 𝑌𝑖𝑗 , 𝛽, 𝛼, 𝜎𝑗
2)  ∝ ∏ {(1 − 𝛼)𝑅𝑖𝑗 𝐼(𝑌𝑖𝑗>𝜉) ∗ 𝛼(1−𝑅𝑖𝑗)𝐼(𝑌𝑖𝑗>𝜉)}𝑖𝑗  ×  
 ∏ {|Σ|−
1










𝛽} ×  𝐼(0 <  𝛼 < 1)  × ∏ {(𝜎2)−𝜆1−1 ∗ exp {
−𝜆2
𝜎𝑗
2 }}𝑗  ×














Based on MCMC Gibbs sampling from the above joint density, we can obtain full conditional 
distributions for each parameter. 
The conditional densities are:  
 𝑃(𝛼 |… ) ~ Beta(Σ𝑖𝑗[(1 − 𝑅𝑖𝑗)𝐼(𝑌𝑖𝑗 > 𝜉)] + 1, Σ𝑖𝑗[𝑅𝑖𝑗𝐼(𝑌𝑖𝑗 > 𝜉)] + 1) 






 𝑃(𝜆1| … ) ~ Normal (







 𝑃(𝜆2| … ) ~ Inv Gamma (𝑐 +
𝑀
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The conditional densities for 𝜎𝑗
2 and 𝜌 are not in the closed form but are proportional to  
 𝑃(𝜎𝑗
2 | … )   ∝  ∏(𝜎𝑗
2 | 𝜆1, 𝜆2) × ∏ 𝑓(𝑌𝑖|
𝑁
𝑖=1 𝑋𝑖𝛽, Σ(𝜎𝑗
2 , … )) 
 𝑃(𝜌| … )   ∝  ∏ 𝑓(𝑌𝑖|
𝑁
𝑖=1 𝑋𝑖𝛽, Σ(𝜌,… )  × I(0 <  𝜌 < 1) 
These parameters are sampled using MH steps with the proposal distributions 
 𝜎𝑗
2 ~ log Normal (log(𝜎𝑗
2)(𝑖−1), ℎ)  
 𝜌 ~TruncNormal (𝜌(𝑖−1), 𝑘) I (0 <  ρ < 1) 
where (𝜎𝑗
2)(𝑖−1) and 𝜌(𝑖−1) represent the values of the parameters at the previous 
iteration(𝑖 − 1).  The values of ℎ and 𝑘 are determined by trial and error so that the proposed 
value is accepted 25%-45% of the time. 
The MCMC sampler depends on data augmentation designed for our MDM to handle the 
MVs in our data. In each iteration of the Markov chain, the missing 𝑌𝑖𝑗s are imputed based on 
values of all current model parameters. The proposed MDM assures simple and efficient 
conjugate sampling for this step. For each missing 𝑌𝑖𝑗 , an indicator variable 𝑍𝑖𝑗 is introduced 
which determines whether 𝑌𝑖𝑗 will be below the LOD threshold 𝜉  (𝑍𝑖𝑗 = 1) or above the 
threshold (𝑍𝑖𝑗 = 0). Conditional on the parameter values and the values of 𝑌𝑖(𝑗′) for the other 










































where 𝜇𝑖𝑗 and ?̃?𝑗
2 represent the usual formulas for the conditional mean and variance for 𝑌𝑖𝑗 
given the 𝑌𝑖(𝑗′)s in the multivariate normal distribution.  
 𝜇𝑖𝑗 =  𝜇𝑖𝑗 + Σ12Σ22
−1(𝑌𝑖(𝑗′) − 𝜇𝑖(𝑗′))  and ?̃?𝑗
2 = Σ11 − Σ12Σ22
−1Σ21 
As the integrals required are all probabilities under the normal distribution, this can be 
efficiently evaluated. Given 𝑍𝑖𝑗 , the value of the missing 𝑌𝑖𝑗 is imputed by 
 𝑍 = 1: 𝑌𝑖𝑗 ~ Truncated Normal (𝜇𝑖𝑗, ?̃?𝑗
2)𝐼(−∞, 𝜉) 
 𝑍 = 0: 𝑌𝑖𝑗 ~ Truncated Normal (𝜇𝑖𝑗, ?̃?𝑗
2)𝐼(𝜉,∞) 
Our MCMC scheme iterates between the above steps for a 2300 iterations after a burn-in of 
200 iterations.  Inference is based on either the posterior sample of model parameters.  
Alternatively, one or more completed data sets can be formed using the sampled MVs which 
can be analyzed using existing (frequentist) methodology. 
3.3 Simulation Studies 
We evaluated the performance of the methods by first evaluating the estimation error. We 
compared the bias and the MSE for the 𝛽 regression coefficients based on the Bayesian 
method and other standard approaches such as zero, mean and minimum imputation. For the 
standard approaches a general linear regression was fit to estimate the 𝛽. We further explored 
the null hypothesis significance testing, where the primary goal is to determine whether a 
particular “null” value of a parameter can be rejected.  We compare the Bayesian approach to 
a general t-test under the alternative imputation choices. The above algorithm produces full 
Bayesian posterior samples, and we need to perform inference on the intercept and treatment 




The design matrix is chosen such that this is represented as the decision between 𝛽𝑗 =
0 or 𝛽𝑗 ≠ 0  for some j.  We then form 100(1 − 𝛼)% equal tail credible intervals and check 
if it contains zero or not.  We can obtain a “Bayesian p-value” by taking the largest 𝛼 such that 
the 100(1 − 𝛼)% CI contains zero, that is, the narrowest CI that contains zero. We then 
evaluate the power, type1 error and the area under the ROC curve (AUC) using the p-values 
from each test to analyze differentially expressed metabolites.  
The simulations were conducted with 100 replicated datasets and are similar in spirit to those 
used in Tutz and Ramzan (2015) . For each replication we generated data with sample sizes 
𝑛 =10 belonging to 2 groups of 5 samples and number of metabolites 𝑚 = 225. The first 100 
metabolites were differentially expressed whereas the remaining 125 were not differentially 
significant. The correlation matrix of metabolites within samples was considered to be 
autoregressive (AR) type correlation, where an AR correlation matrix of order one is defined 
by pairwise correlations 𝜌|𝑖−𝑗|, for metabolites 𝑖, 𝑗 = 1,… ,𝑀.  
The means of group 1 metabolites generated from a Uniform(−5,5) distribution. The 
differentially expressed metabolites (100 out of 225) are one unit larger in group 2. In the AR 
type correlation, the correlation 𝜌 = 0.8 and the variance was 1. For the degree of missing, 
three levels were studied: 9% missing, 15% missing and 30% missing. Missing data were 
created based on the two kinds of missingness, MNAR and MAR. Technically, the latter are 
generated by MCAR, though a MAR mechanism can be exploited for imputation since the 
metabolite values are highly correlated. Within each level of missing, a one-third and two-third 
combination was used to create both MNAR and MAR. For example in 9% missing, we 
considered 6% as MNAR and 3% as MAR. Data below the given MNAR percentile was 




The datasets with missing values were passed through a cleaning process where metabolites 
with more than 50% missing observations were eliminated individually.  
3.4 Results 
In this section, we present the results of the simulation studies comparing the performance of 
the Bayesian method with the three standard approaches. Table 22 shows the average bias and 
MSE based on 100 replications. We consider the accuracy for the intercept, treatment effect 
across the differentially expressed metabolites (real value =1) and the treatment effect across 
the non-differentially expressed metabolites (real value =0).  As can be seen, the results show 
that the MSE for the Bayesian method is lower compared to the other methods for the 
intercepts and the treatment effects. Table 23 shows the average power, type1 error and the 
AUC based on the Bayesian method and the standard approaches. The power and AUC for 
the Bayesian method is higher compared to the other methods whereas the Type 1 error is not 
lower than the compared methods. Figures 8 and 9 plots the distribution of the Bias and MSE 
values for Bayes, zero, mean and minimum by percent missing for the intercepts, significant 
treatment effect and non-significant treatment effect. Figure 10 plots the results from the 
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Table 22: Average Bias and MSE of 100 datasets, 100 samples by 225 metabolites for Bayes, 
zero, minimum and mean methods.  
Total missing was considered at 9%, 15% and 30%, and within each missing, MNAR was 
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Table 23: Average power, type 1 error and AUC of 100 datasets, 100 samples by 225 
metabolites for Bayes, zero, minimum and mean methods.  
Total missing was considered at 9%, 15% and 30%, and within each missing, MNAR was 






Figure 8:  Boxplots of Bias for Bayes, Zero, Minimum and Means for 100 datasets, 10 samples 
by 225 metabolites.  








Figure 9: Boxplots of MSE for Bayes, Zero, Minimum and Means for 100 datasets, 10 samples 
by 225 metabolites.  








Figure 10: Boxplots of Power, Type1 Error and AUC for Bayes, Zero, Minimum and Means 
for 100 datasets, 10 samples by 225 metabolites.  







In this work, we have proposed a Bayesian methodology to impute MVs, especially when the 
sample size is small. When metabolites occur at low abundance, below the detection limit of 
the instrumentation, we can consider it as missing not at random. In contrast, missing values 
resulting from technical errors are considered missing at random. To this end, we introduce a 
Bayesian model that incorporates the data augmentation that models imputing MVs handling 
the truncated data. Since MNAR is due to the detection limit, we consider the detection limit 
as a truncation point and assume that the metabolite follows a truncated normal distribution. 
The simulation results show that the proposed method performs better than standard 
approaches when there is missing data due to a threshold LOD.  
In our simulations we evaluated only one size dataset which had small samples (10 samples by 
225 metabolites). The LOD was calculated based on the missing percentage. For instance in 
9% missing (where 6% was considered as MNAR) the 6% quantile for the complete data was 
considered as the LOD where we considered everything below that value as missing.  The 
results shown in the tables are based on when the MNAR percentage is greater than the MAR 
percentage (e.g. for 9% total missing, 6% is MNAR and 3% is MAR). In the cleaning process 
(which removes metabolites with >50% MVs in each group) we are removing more 
metabolites whose values are concentrated near the LOD. For example in our case, after 
screening we reduced the metabolites to an average of about 207 metabolites for 15% missing 
and 186 metabolites for 30% missing out of the original 225. We included analysis looking at 
estimation efficiency (bias and MSE) and the impact on hypothesis testing whether metabolites 




An important limitation to our methodology is the reliance on the normality assumption for 
modeling the metabolite abundance. In our simulation study we investigated data from a 
normal distribution, whereas in many cases metabolite data may be non-normally distributed. 
In these cases we suggest to first transform the data to normality, then impute the values and 
lastly transform back. Hypothesis testing and inference may also be performed on 
transformation scale.  
3.6 Conclusions 
In conclusion, the simulation results reveal that compared with standard approaches such as 
zero, mean and min imputation, the Bayesian method is a coherent approach for imputing 
high dimensional data where there is missingness partially due to a truncation (detection) 
threshold. Results based on simulated data show that the Bayesian method generally has lower 
MSE values compared to the other three simpler imputation algorithms (zero, mean, and 
minimum value imputation) when there is both missing at random and missing due to a 
threshold value.  Assessment based on hypothesis testing also demonstrates that the Bayesian 
method generally outperforms the other three methods.  However, the approach has a 
computation expense due to the extensive iterations usage in MCMC algorithms. Even though 
this study is based on metabolomic datasets, our findings are more generally applicable to 
other types of high-dimensional data that contains missing values associated with an LOD, for 
instance proteomics data and  delta-CT values from qRT-PCR array cards (Warner, 








BIOLOGICAL IMPACT OF IMPUTATION METHODS ON 
DOWNSTREAM ANALYSES 
4.1 Background 
High-throughput technologies, such microarrays or mass spectrometry (MS) suffer from 
missing values (MV) due to various experimental reasons. The issues posed by MVs are well-
known in statistical data analysis literature (Little and Rubin, 2002). Standard downstream 
statistical methods have been developed to analyze complete data sets, where the rows 
represent the cases and the columns represent the variables measured. Although in many 
applications, these data matrices are not complete where variables for some cases cannot be 
measured technical problems, or the measurements are not reliable or obtainable for certain 
samples. Typically in high-throughput technology the missing values occur in a large number, 
e.g in metabolomics studies MVs are reported to comprise around 10–40% of data (Armitage 
et al, 2015) and thus it is not practical to simply remove samples with MVs as this can lead to 
selection bias.  
Downstream analyses via multivariate methods require a complete dataset. MVs are handled 
differently and thus affects the interpretation and statistical inference. The most common 
approach used in handling MVs is case deletion, wherein this method only completed cases 
with no MVs are included in the analysis. This method leads to a smaller sample size which 
results in low power (White & Carlin, 2010; Harel et al., 2012). The other widely used approach 




forward method but also a dangerous way of dealing with missing values. Statistical analysis 
performed on datasets imputed by single imputation method may be biased as the approach 
does not consider the uncertainty of the imputed values. The common single imputation 
methods include mean, zero, half minimum and median imputation where the MVs are 
replaced by the mean, zeros, half of the minimum and median of the variable respectively. The 
magnitude of the covariances and correlation also decreases by limiting the variability, and this 
method often causes biased estimates, irrespective of the underlying missing data mechanism 
(Eekhout et al., 2012; Enders, 2010). Other single imputation methods that have been 
developed recently include the k-nearest neighbor (kNN), random forest (RF), Bayesian 
principal component analysis (BPCA), probabilistic principal component analysis (PPCA), and 
singular value decomposition (SVD) imputation (Schafer and Graham, 2002). 
Within the microarray arena, there is noticeable presence of MV imputation methods and 
downstream analysis. In a recent comparative study by Brock et al (2008), eight MV imputation 
methods were investigated on different datasets and concluded that no single best MV 
imputation method exists but BPCA, LLS and LSA performed among the best. There is 
limited noticeable literature in the comparison of MV imputation methods in metabolomics. 
Gromski et al (2014), analyzed different MV imputation methods and their influence on 
multivariate analysis. They looked at five MV imputation methods: zero, mean, median, KNN, 
and Random Forest (RF) imputation and their influence on unsupervised and supervised 
learning and the final impact on the final output in terms of biological interpretation. Their 
results showed that the imputation methods have a considerable effect on the classification 
accuracy. Based on the data, they recommend that RF is better than the other methods as the 
classification rates for both supervised methods outperforms the other imputation methods. 




can significantly affect the results and interpretation of analyses of metabolomics data. They 
compared eight common MV imputation methods (substitution with a small predefined value, 
half minimum, mean, median, KNN, BPCA, multivariate imputation, REP (MV is substituted 
with average intensity of nearest peaks from the raw measurements of technical replicates)) 
and their impact on univariate and multivariate analysis. They concluded that the treatment of 
missing data is a very important step in data processing and suggest that KNN method imputes 
the most reliable values and is preferred method over the other methods. Armitage et al. (2015) 
tested four MV imputation methods (median, KNN, half minimum and zero) on different 
statistical tests and concluded that KNN was the best approximation for the real missing data.  
There is noticeable absence in the literature of a comprehensive study of how the MV 
imputation methods affect the different downstream analyses in metabolomics such as 
biomarker detection, classification and cluster analysis. We perform a comprehensive and 
systematic evaluation to examine the biological impact of MV imputation in the three areas of 
downstream analyses: biomarker detection, classification and cluster analysis. To our 
knowledge, this is the first comprehensive evaluation study to focus on all three major 
downstream analyses.  
4.2 Methods 
To perform a comprehensive comparison and evaluation, we included six MV imputation 
methods and three major downstream analyses were considered; differential abundance, 
classification and clustering. 
MV imputation methods 
We included six MV imputation methods for evaluation:  zero, minimum, mean, KNN-CR, 




Downstream analyses methods 
We consider the three major types of downstream analyses to evaluate the biological impacts 
of MV imputation methods; differential abundance (DA) metabolite detection, classification 
and metabolite clustering. The specific methods evaluated are described below. 
DA metabolite detection 
We included the moderated t-test (limma), moderated t-test with fold-change (TREAT), and 
the standard t-test analysis. Smyth (2004) proposed an empirical Bayes (eBayes) approach 
which is a moderated version of the t-test that averages between the per-feature sample 
variance and a global (pooled) estimate of the variance. The TREAT method (McCartthy et al 
(2009)) is an extension to the eBayes method which tests whether differences in feature 
expression are above a given threshold.  
Classification analysis 
We included support vector machines (SVM), partial least squares discriminant analysis (PLS-
DA) and k nearest neighbors (KNN).  
Metabolite clustering analysis 
We included K-means, hierarchical clustering and self-organizing maps (SOM) (Kohonen, 
2001). Since the number of clusters K usually cannot be determined for a given dataset, we ran 
metabolite clustering using different choices of K, such as K = 10 and 15. 
Assessment measures 
We evaluated the performance of the imputation methods by using the root mean squared 




estimated values and the original true values, when the original true values are known. The 
following simulation procedure from a complete dataset (CD) with no MVs is performed. 
MVs are generated by removing a proportion 𝑝 of values from the complete data to generate 
data with MVs (MD). The MVs are then imputed as ?̂?𝑖𝑚 (where 𝑦𝑖𝑚 is the intensity of 
metabolite 𝑚 (1 ≤ 𝑚 ≤ 𝑀) in sample 𝑖 (1 ≤ 𝑖 ≤ 𝑁)) using the given imputation method 
(ID). Finally, the root mean squared error (RMSE) is used to assess the performance by 
comparing the values of the imputed entries with the true values:  
𝑅𝑀𝑆𝐸 =  √
1
𝑛(ℳ) 
∑ (?̂?𝑖𝑚 − 𝑦𝑖𝑚)2
𝑦𝑖𝑚 ∈ ℳ
, 
where ℳ is the set of missing values and 𝑛(ℳ) is the cardinality or number of elements in ℳ. 
Metabolite list concordance index (MLCI) for DA metabolite detection 
Suppose CD, MD and ID are obtained using the imputation methods and by applying a 
selected DA metabolite detection method (eBayes, TREAT, and t-test ), we obtain a 
metabolite list from CD and another metabolite list from ID. The MLCI is defined as:  









− 1 , 
where 𝑀𝐶𝐷 is the list of statistically significant metabolites in the complete data, 𝑀𝐼𝐷 is the list 
of statistically significant metabolites in the imputed data, and 𝑀𝐶𝐷
𝐶  and 𝑀𝐼𝐷
𝐶  represent their 
complements, respectively.  The metabolite list taken from the complete dataset is considered 
as the gold standard and a high value in MLCI indicates that the metabolite list from the 
imputed data is similar to that from the complete data. MLCI is correspondent to the Youden 




 Youden Index (YI)  
We employ YI as a measure to evaluate the impact of MVs in classification. YI is defined as 
sensitivity + specificity − 1. We can directly calculate the YI of the prediction result from each 
imputed data because we know the true class labels of the samples in this supervised learning. 
We expect a good MV imputation method to generate a high YI. 
Adjusted Rand Index (ARI) 
The ARI (Hubert, 1985) is commonly used to evaluate the similarity between any two 
clustering results. Similar to MLCI we use the clustering result from the complete data as the 
gold standard and compare it with the imputed data clustering result. A higher ARI value 
indicates higher similarity between any two clustering results and that the MV imputation 
procedure leads to a smaller impact on the metabolite clustering analysis.  
 




4.3 Real Data Studies 
Atherothrombotic Data 
We used the human atherothrombotic myocardial infarction (MI) metabolomics data. The 
data was identified between two groups, those with acute MI and those with stable coronary 
artery disease (CAD). Acute MI was further stratified into thrombotic (Type1) and non-
thrombotic (Type2) MI. The data was collected across four time points and for the context of 
this research we used the baseline data only. The three groups, sCAD, Type1 and Type2 had 
15, 11, and 12 patients with 1032 metabolites. The sCAD had 685 metabolites with complete 
values, 39 metabolites with complete missing, and 308 metabolites had 10.2% missing, the 
Type1 group had 689 metabolites with complete values, 43 metabolites with complete missing 
and 300 metabolites had 9.8% missing whereas the Type2 group had 610 metabolites with 
complete values, 66 metabolites with complete missing and 356 metabolites had 12.3% 
missing. The LOD for this dataset is considered as the minimum value of the dataset as 
commonly used in untargeted metabolomics. Plasma samples collected from the patients were 
used and 1032 metabolites were detected and quantified by GC-MS and ultra-performance 
(UP) LC-MS in both positive and negative ionization modes. Details of the experiment are 
described in DeFilippis et al (DeFilippis, Chernyavskiy et al. 2016). 
Due to small sample sizes in metabolomics datasets, we used a simulation approach originally 
designed to resemble the multivariate distribution of gene expression in the original microarray 
data (Parrish, Spencer Iii et al. 2009). Since our Atherothrombotic data had missing values we 
first imputed missing values based on the KNN-CR method and then used the simulation 
method to simulate 100 datasets. The different groups were considered as independent 




missingness and screening as used in the simulation studies, with sample sizes of 25 and 50 
for the human atherothrombotic dataset. For each simulation, we selected all the metabolites, 
and artificially generated a total of 60 differentially expressed metabolites with varying effect 
sizes between the two study groups (10 metabolites each with effect sizes 0.5, 1.0, 1.5, 2.0, 3.0, 
and 4.0). Sample sizes of 25 and 50 per group were evaluated, and a total of 100 simulations 
were conducted for each scenario. We used the generated simulated datasets for the three 
downstream analyses. For the DA, the p-Values from each method were adjusted based on 
the Benjamini–Hochberg (Benjamini Y et al (1995)) method to maintain an overall false-
discovery rate of 0.05. Overall MLCI was estimated based on the mean of the 100 simulations. 
For the clustering analysis we clustered the metabolites based on 10 and 15 clusters.  
 
4.4 Results 
We conducted a simulation study based on the real datasets to further validate our results. 
Tables 24 (a-c) show the results of the MLCI based on the three DA metabolite detection test 
on the sCAD group of the human atherothrombotic data for the three different missing 
mechanism and two different sample sizes. Based on the table, we can see that KNN-TN 
performs little better than the rest of the imputation methods and the results seem consistent 
with the two sample sizes (25 and 50) and three missingness (9%, 15% and 30%). Table 25 (a-
c) show the results of the ARI based on the three clustering methods on the sCAD group of 
the human atherothrombotic data for the three different missing mechanism and two different 
sample sizes. Table 26 (a-c) show the results of the YI based on the three classification 
methods on the sCAD group of the human atherothrombotic data for the three different 




of the MLCI, ARI and YI for KNN-TN, KNN-CR, KNN-EU, Zero, Mean and Min by 






Table 24: Average MLCI of 100 simulations using the human atherothrombotic dataset sCAD 
group for Zero, Min, Means KNN-TN, KNN-CR and KNN-EU 
SAMPLE 
SIZE 





















































































Table 24a. Average MLCI of 100 simulations using the human atherothrombotic dataset 
sCAD group for Zero, Min, Means KNN-TN, KNN-CR and KNN-EU. Total missing was 





























































































Table 24b. Average MLCI of 100 simulations using the human atherothrombotic dataset 
sCAD group for Zero, Min, Means KNN-TN, KNN-CR and KNN-EU. Total missing was 





























































































Table 24c. Average MLCI of 100 simulations using the human atherothrombotic dataset 
sCAD group for Zero, Min, Means KNN-TN, KNN-CR and KNN-EU. Total missing was 





Table 25: Average ARI of 100 simulations using the human atherothrombotic dataset sCAD 
group for Zero, Min, Means KNN-TN, KNN-CR and KNN-EU 
SAMPLE 
SIZE (K) 



















































































































































  0.484 
(0.060) 














Table 25a. Average ARI of 100 simulations using the human atherothrombotic dataset sCAD 
group for Zero, Min, Means KNN-TN, KNN-CR and KNN-EU. K is the cluster size, K = 










































































































































































Table 25b. Average ARI of 100 simulations using the human atherothrombotic dataset sCAD 
group for Zero, Min, Means KNN-TN, KNN-CR and KNN-EU. K is the cluster size, K = 










































































































































































Table 25c. Average ARI of 100 simulations using the human atherothrombotic dataset sCAD 
group for Zero, Min, Means KNN-TN, KNN-CR and KNN-EU. K is the cluster size, K = 





Table 26: Average YI of 100 simulations using the human atherothrombotic dataset sCAD 
group for Zero, Min, Means KNN-TN, KNN-CR and KNN-EU. 
SAMPLE 
SIZE 





















































































Table 26a. Average YI of 100 simulations using the human atherothrombotic dataset sCAD 
group for Zero, Min, Means KNN-TN, KNN-CR and KNN-EU. Total missing was 




























































































Table 26b. Average YI of 100 simulations using the human atherothrombotic dataset sCAD 
group for Zero, Min, Means KNN-TN, KNN-CR and KNN-EU. Total missing was 




























































































Table 26c. Average YI of 100 simulations using the human atherothrombotic dataset sCAD 
group for Zero, Min, Means KNN-TN, KNN-CR and KNN-EU. Total missing was 






Figure 12: Boxplots of MLCI for KNN-TN, KNN-CR, KNN-EU, Zero, Mean and Min for 
100 datasets, Sample size = 25.  
Total missing was considered at 9%, 15% and 30% and within each missing MNAR is greater 







Figure 13: Boxplots of ARI for KNN-TN, KNN-CR, KNN-EU, Zero, Mean and Min for 
100 datasets, Sample size = 25 and K = 15  
Total missing was considered at 9%, 15% and 30% and within each missing MNAR is greater 






Figure 14: Boxplots of YI for KNN-TN, KNN-CR, KNN-EU, Zero, Mean and Min for 100 
datasets, Sample size = 25  
Total missing was considered at 9%, 15% and 30% and within each missing MNAR is greater 






The objective of this study was to evaluate the impact of MV imputation method on 
commonly performed downstream analyses. Although several prior studies have investigated 
the impact of MV imputation on individual analysis only, there has been no extensive analysis 
approach on the impact of MVs. Our investigation on the MVs imputation the RMSE measure 
was found to be the lowest with the KNN-TN method from the previous studies. In 
evaluating the biological impact of MV imputation on downstream analyses commonly carried 
out after MVs, we found that for detection of DA metabolites, the KNN-TN performed well 
compared to the other methods.  In contrast for classification analysis, the impact of MV 
imputation was mixed. Overall, KNN-TN performed best in most cases, but KNN-CR or 
KNN-EU performed better in some cases. While DA metabolite detection and classification 
presented different results, the impact on clustering was also mixed where KNN-TN 
performed the best in most of the cases among the different methods. Our selection of 
biological impact measures for the effect of MV imputation on downstream analyses was 
motivated by choosing a measure that is both comprehensive and intuitive. The MLCI and YI 
were selected because they capture both the sensitivity and specificity of the result in a single 
measure, and the adjusted Rand index is a well-known and widely used measure of 
concordance between two clustering partitions. The primary analysis in our study is based on 
the downstream analysis of the logged data, a typical practice before analysis.  
4.6 Conclusions 
Based on the results, we conclude by highlighting the results from our study. Prior to deciding 
which imputation algorithm to use for MVs in metabolomics data, it is helpful for investigators 
to know which areas of downstream analysis are even impacted by MV imputation. The 




metrics, KNN based on truncation estimation is a competitive approach for all the three 
different downstream analyses. Results based on real data simulations show that the proposed 
method (KNN-TN) generally has higher MLCI, ARI and YI values compared to the other 
two KNN methods and simpler imputation algorithms (zero, mean, and minimum value 








CONCLUSIONS AND FUTURE RESEARCH 
 
This dissertation consisted of three research projects. The first project was a novel approach 
for MV imputation method based on truncated normal distribution with the nearest neighbors 
approach. The means and standard deviations of the metabolites were first estimated based 
on the truncated normal distribution with the LOD as the truncation point using the Newton 
Raphson algorithm. We conducted extensive simulation studies and real data set simulations 
to show that the proposed method outperforms from the standard approaches. With the 
parametric model, small sample size was a bottleneck and thus led to the second project where 
we employed data augmentation with a Bayesian model based on MCMC. The initial results 
on the Bayesian model show that with small samples the Bayesian model performs well 
compared to the other standard methods. We further evaluated the impact of MV imputation 
methods on three different downstream analyses; DA metabolite detection, classification and 
clustering.  We conducted a comprehensive study to examine the impact on MV imputation 
methods and based on the results the KNN-TN method performs better or similar to KNN-
CR but performs better compared to other methods. Detection of DA metabolites was the 
most sensitive analysis to the choice of imputation method while classification was the least 
sensitive and clusterting was intermediately affected.   
The success of a MV imputation algorithm cannot be solely measured by its accuracy in 




of greater importance. Further, the choice of an optimal imputation algorithm may depend on 
the underlying structure of the data. In the future studies, we want to extend and perform 
extensive simulations and extend the performance of MV imputation methods to other 
existing methods such as random forest, local least squares estimation etc. While previous 
studies have investigated the downstream impact of MV imputation in metabolomics, they 
have generally done so based on only a single imputation pass (Gromski et al and Hrydziuszko 
et al). By using multiple simulated datasets and more real datasets, we want to provide a more 
definite answer to the question of biological impact of missing value imputation in 
metabolomics. With the Bayesian framework, we want to extend the model to different 
correlation structures and evaluate more simulated data combinations and also apply on real 
datasets. We further want to specifically investigate how robust the Bayes method does by 
only using MNAR and comparing it with minimum imputation and then only using MAR and 
comparing it with the mean imputation. The impact of our novel approaches in project 1 and 
project 2 is limited without open-source software to implement them. We want to provide 
users with a robust package and user-friendly interface for missing value imputation in 
metabolomics studies. To permit multiple developers of the software, R packages will be 
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Details of NR Procedure 
For notational convenience we define the probability 𝑃(𝑌 ∈ (𝑎,∞)|𝜇, 𝜎2) as  








Interchanging differentiation and integration, the first derivatives of the above equation 
with respect to 𝜇 and 𝜎 are 








 𝑑𝑦, and 
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Using the above derivatives, the gradient (G) (first partial derivative) with respect to the 
parameters is  
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Daily Hemodialysis: A Clinical Experience. Poster. ASDIN 2013 Scientific Meeting, 





AHA- Tobacco Regulation and Addiction Center Annual Meeting, Louisville, KY, March 
2017 
 
ENAR 2017, Washington DC, March 2017 
 
Fostering Diversity in Biostatistics Workshop ENAR 2017 
 
Research Louisville 2016, Louisville, KY, October 2016 
 





Fostering Diversity in Biostatistics Workshop JSM 2016 
 
AHA- Tobacco Regulation and Addiction Center Annual Meeting, Louisville, KY, April 
2016 
 
UT-ORNL-KBRIN Bioinformatics Summit 2016, Lake Barkley State Park. KY, April 2016 
 
ENAR 2016, Austin, TX, March 2016 
 
Fostering Diversity in Biostatistics Workshop ENAR 2016 
 
Research Louisville 2015, Louisville, KY, October 2015 
 
Joint Statistical Meetings 2015, Seattle, WA, August 2015 
 
UAB 3rd Metabolomics Workshop 2015, Birmingham, AL, June 2015 
 
UT-ORNL-KBRIN Bioinformatics Summit 2015, Paris Landing State Park, TN, March 
2015 
 
AHA- Tobacco Regulation and Addiction Center Annual Meeting, Louisville, KY, March 
2015 
 
KBRIN Next Generation Sequencing (NGS) Workshop, Lexington, KY, July 2014 
 
UT-ORNL-KBRIN Bioinformatics Summit 2014, Lake Barkley State Park. KY, April 2014 
 
Southern Regional Council on Statistics (SRCOS), Burns, TN, June 2013 
 






Travel Award SRCOS 2013 Burns TN, June 2-5 2013 
KBRIN Support Scholarship, University of Louisville, 2010 - 2011 
Scholarship Award, University of Louisville International Center, 2010 
 
Scholarship Award, University of Louisville International Center, 2009 
Scholarship Award, University of South Alabama Department of Mathematics and Statistics, 
2009 





Sushila Mishra Memorial Mathematics and Statistics Scholarship, University of South Alabama, 
Spring 2009 
 
TECHNICAL SKILLS:  
Statistics: Microarray Data Analysis, Bioinformatics Data Analysis, SAM analysis 
 
Statistical Software: R, SAS, SPSS, Minitab, WinBUGS, Matlab, Bioconductor, Sigma plot 
 
Other application software: Microsoft Office, LaTeX, NimbleScan software, DAVID Clustering, 
Sample Size Calculators, Octave, Mathematica 
 
Biological Applications: BLAST, NCBI, KEGG pathway, UniProt, Swiss-Prot, TrEMBL, 
GenBank, Ensembl Genome Browser, UCSC Genome Browser, EPD, TRASFAC, Protein 
Information Resource, dbSNP, miRbase, miRanda and Target Scan   
 
Programming Languages: C++, Java, Perl, SQL 
 
PROFESSIONAL SOCIETIES: 
American Statistical Association (since 2010) 
The International Biometrics Society Eastern North American Region (since 2016) 
Rotaract Club of Greater Louisville (Secretary: Sept 2015 – Dec 2016) 
Student Chapter ASA University of Louisville (Treasurer: Aug 2015 – Aug 2016) 
 
HONORS: 
Deans Citation Award 2017 (Nominated and Awarded) 
University of Louisville Dean’s List Aug 2009 – Dec 2013 
Golden Key International Honour Society 2011- Current 
Summa Cum Laude May 2a009 
Best Math and Statistics Student May 2009 
University of South Alabama Deans List Jan 2008 – May 2009 
Macomb Community College Deans List Jan 2004 – May 2007 




Silver Standard of the President’s Award Kenya: 2002 
Bronze Standard of the President’s Award Kenya: 2001 
 
LANGUAGE SKILLS:    
Gujarati (Mother tongue)       
English (Read, write and speak)  
Hindi (Read, write and speak)  




Aug 2011 – Dec 2016: International OASIS University of Louisville (Head Leader) 
 
Jan 2016 – Current: Gujarati Samaj of Greater Louisville (Nonprofit 501c3) (Board) 
 
Aug 2015 – Aug 2016: Biostatistics Club University of Louisville (Treasurer) 
